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Perfluoroalkyl substances (PFAS), a family of environmental toxicants, are 
ubiquitous in the environment and the human population. PFAS are manmade 
chemicals that have been widely used in manufacturing since the 1940s. PFAS 
are extremely resistant to degradation leading to their accumulation within the 
environment and the general population. The most concentrated PFAS member 
present in the general population, perfluorooctanesulfonic acid (PFOS), has 
been linked to suppressed vaccine response, high serum cholesterol, low fetal 
birth weight, thyroid disease, increased markers of liver injury, and even certain 
types of cancers. PFOS was voluntarily phased out of manufacturing due to its 
bioaccumulutive and toxic properties by the year 2015. In 2016, the EPA 
dramatically lowered the federal health advisory level of PFOS in drinking water 
to 70ppt due to the emerging evidence of its toxicity. After the phase out of 
PFOS, replacement PFAS members perfluorononanoic acid (PFNA) and 
perfluorohexanesulfonic acid (PFHxS) took its place and began to rise in 
environmental and human serum concentrations. Currently, there is no federal 
health advisory level in place for PFNA or PFHxS. The relative toxicity of these 
replacement PFAS compounds is still being evaluated in the literature and by 
regulatory officials.  
PFAS, including PFOS, PFNA, and PFHxS, are known to augment hepatic lipid 
accumulation and steatosis in animal studies. However, there is a lack of 
knowledge concerning their potential role in the increasing incidence of 
nonalcoholic fatty liver disease (NAFLD) in the global population. It is difficult to 
 
 
study the potential link between PFAS exposure and NAFLD due to the lack of 
an accurate and widely accepted serum biomarker for the NAFLD. PFAS levels 
are typically measured through serum samples, however NAFLD is often 
diagnosed via liver biopsy. Obtaining human liver biopsy data that is matched 
to serum samples characterized for PFAS concentration has proven 
prohibitively difficult. The vast majority of studies that have evaluated PFAS 
exposure in the liver have utilized standard chow diets, high doses, and acute 
exposures. In the human population, NAFLD is most commonly induced by poor 
diet and lifestyle over time. The present work aimed to understand how 
environmentally relevant exposure to PFAS affect the onset and progression of 
NAFLD in the presence of a poor diet over a subchronic or chronic timeframe. 
Furthermore, this work sought to uncover the mechanistic drivers of these 
PFAS-diet interactions.    
In manuscript 1, male C57BL6 mice were fed with either a low fat diet (10% kcal 
from fat) or a moderately high fat diet (45% kcal from fat) with or without PFOS 
or PFNA 0.0003% w/w in feed for 12 weeks. Proteomics and transcriptomics 
were utilized to explore the mechanistic pathways driving the liver pathology. 
The aim of this study was to assess and explore the impact of diet-PFAS 
interactions on the onset of NAFLD using a subchronic, low-dose PFAS 
exposure. In addition, we sought to compare the toxicity of PFOS to the 
unregulated PFNA. In manuscript 2, male C57BL6 mice were fed with either a 
low-fat diet (11% kcal from fat) or a high fat (58% kcal from fat) high 
carbohydrate (42g/L) diet with or without PFOS or PFHxS, in feed (0.0003% 
 
 
w/w) for 29 weeks. Sera lipidomics, as well as hepatic proteomics, gene 
expression, and pathology were used to assess diet-PFAS interactions. The aim 
of manuscript 2 was to assess the impact of PFAS-diet interactions on the 
progression of nonalcoholic fatty liver (NAFL) to the inflammatory stage, 
nonalcoholic steatohepatitis (NASH) using a chronic low-dose PFAS exposure. 
Moreover, we compared the relative toxicity of PFOS to an unregulated 
replacement, PFHxS.  
In manuscript 1, PFASs were augmented the onset of fatty liver only in 
combination with a low fat diet. Yet in manuscript 2, PFASs worsened 
macrovesicular steatosis and inflammation within the high fat high carbohydrate 
diet relative to combination with a low fat diet. Both studies revealed that diet 
composition as well as slight alterations in PFAS structure exert significant 
influence on PFAS tissue partitioning and excretion, liver pathology, lipids, and 
the resulting hepatic biochemical signature. Finally, diet-PFAS interactions may 




I would like to thank my major professor Dr. Angela Slitt.  Not only was she a 
fantastic PhD mentor, but she encouraged me as an undergraduate student to 
pursue a graduate degree. This guidance at a critical time was transformative 
to my life trajectory. Dr. Slitt has continued to guide me throughout my graduate 
studies and aided in my growth professionally and as an independent thinker. I 
will forever be grateful for her support.  
Sources, Transport, Exposure, and Effects of PFASs (STEEP), an NIH funded 
superfund group, provided critical funding that enabled me to explore and 
develop big data techniques. I am grateful to the STEEP training core for aiding 
my development professionally and for embedding me in inter-disciplinary 
science. I am also thankful to my committee members, Dr. Bongsup Cho, Dr. 
Rainer Lohmann, and Dr. Geoffrey Bothun, for offering their time, 
encouragement, input, and support along my training. I appreciate the 
opportunities my committee provided me to grow as a speaker, scientist, and 
trainee along the way.  
Last but certainly not least, I am grateful for my colleagues, friends, and family 
who have loved and supported me, shared expertise and equipment, and 
overall helped me get through the toughest challenges of graduate school. I 
cannot imagine reaching this point without the amazing support system I have 
been blessed with. Thank you for always believing in me and reminding me what 





This dissertation was prepared in the style of manuscript format. The contents 
are divided into two manuscripts that evaluate the relationship between PFAS 
structure, diet, and non-alcoholic fatty liver disease (NAFLD). The first 
manuscript explores the interaction between a moderately high fat diet and 
PFASs in the liver and investigates further alterations in hepatic response 
related to the PFAS functional head group. This was achieved in a C57BL6 
mouse model of diet-induced obesity using transcriptomic and proteomic 
techniques. This manuscript is the first to confirm the diet specific response to 
PFOS in the liver, expand this to PFCAs, and to characterize diet-PFAS effects 
on the hepatic signature. The second manuscript focuses on PFAS-diet 
interactions in a proinflammatory high-fat high carbohydrate diet and the 
additional structural impact of PFAS chain length. This was investigated in 
C57BL6 mice utilizing proteomic and lipidomic techniques. This manuscript is 
the first to characterize direct PFAS-diet effects on the sera lipidome and direct 
serum to liver partitioning. Both manuscripts have been prepared for submission 
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Perfluoroalkyl substances (PFASs) are a family of toxicants universally detected 
in human serum and known to cause dyslipidemia in animals and humans. Non-
alcoholic fatty liver disease (NAFLD) is most prevalent form of liver disease in 
the United States. This study explored diet-PFAS interactions and their potential 
to potentiate NAFLD. Male C57BL6 mice were fed with either a low-fat diet (10% 
kcal from fat) or a moderately high fat diet (45% kcal from fat, HFD) with or 
without perfluorooctanesulfonic acid (PFOS) or perfluorononanoic acid (PFNA) 
at a low dose of 0.0003% w/w in feed for 12 weeks. Livers were excised for 
histology and quantification of PFASs and lipids. Proteomics and 
transcriptomics were utilized to conduct mechanistic pathway exploration.  The 
HFD increased hepatic steatosis.  Surprisingly, PFOS and PFNA protected 
against the onset of hepatic lipid accumulation and inflammatory progression in 
the high fat diet. Genes and proteins related to lipid metabolism, synthesis, 
transport, and storage were modulated by PFAS exposure and further impacted 
by the presence of dietary fat. When combined with a high fat diet, PFOS and 
PFNA attenuated the onset of NAFLD suggesting that dietary fat impacts the 
behavior of PFASs in vivo. Furthermore, both dietary fat content and the 
chemical functional head group exerted significant influence on hepatic PFAS 








Non-alcoholic fatty liver disease is described by the American Liver Foundation 
(ALF), as the excessive accumulation of fats in the liver in the absence of 
alcohol use. NAFLD is a spectrum disease that can be broken down into three 
distinct stages. The first hit, called fatty liver, is first diagnosed when the fat 
content of the liver accounts for greater than 5-10% of the liver weight 
(Diagnosis of NAFLD & NASH | NIDDK). According to the American Liver 
Foundation, up to 30 – 40% of adults and 10% of children in the US are currently 
afflicted with NAFLD (Liver Disease Statistics - American Liver Foundation). As 
a silent disease, fatty liver is difficult to diagnose due to the absence of 
symptoms and the lack of both non-invasive and reliable diagnostic tests. 
Currently, diagnosis is best achieved through liver biopsy and there remains no 
FDA approved drug for treatment (El-Agroudy et al., 2019). While obesity, 
metabolic syndrome, and diabetes are all known risk factors for NAFLD, the role 
of environmental toxicants as risk factors is not well understood (Duseja and 
Chalasani, 2013). 
Perfluoroalkyl substances (PFASs) are man-made chemicals used in 
manufacturing of Teflon, aqueous film forming foams (AFFF), food packaging, 
and stain resistant sprays for their unique surfactant and anti-stick properties 
(Buck et al., 2011). These long-chain fluorinated structures are extremely 
resistant to degradation leading to their accumulation in water sources, dust, 
and even ambient air (Hu et al., 2016; Winkens et al., 2018; Barber et al., 2007). 




screening of human serum samples in the USA revealed PFASs are detectable 
in over 98% of the general population (Calafat et al., 2007). PFASs that have 
become ubiquitous include, among others, perfluorooctanesulfonic acid (PFOS) 
and perfluorononanoic acid (PFNA) (Kato et al., 2011; Olsen et al., 2017). PFOS 
and PFNA are slow to excrete from the human body with half-lives spanning 
several years, 5.4 and 4.3 years respectively (Olsen et al., 2007) (Zhang et al., 
2013). Once in the body, PFOS and PFNA distribute mainly to protein rich body 
compartments such as serum and liver (Jian et al., 2018). This distribution 
pattern leads to relatively high exposure of PFASs to hepatocytes, increasing 
potential risk for hepatic toxicity. 
While the lifetime effects of chronic PFAS exposure remain uncertain, PFASs 
have been associated with the following adverse human health effects: impaired 
immune function (Grandjean et al., 2012), elevated serum cholesterol (Nelson 
et al., 2010), thyroid disease (Ballesteros et al., 2017), low fetal birth weight 
(Shoaff et al., 2018), elevated serum markers of liver injury (Salihovic et al., 
2018), and even kidney and testicular cancer (Nicole, 2013). PFASs are 
significantly associated with elevated serum ALT, however, the mechanism of 
liver injury remains uncertain. Studies conducted in mice (Wan et al., 2012)(Das 
et al., 2017), rats (Curran et al., 2008a), and cynomolgus monkeys (Seacat et 
al., 2002) have demonstrated that some PFAS members augment lipid 
accumulation and steatosis in the liver at high doses. Likewise, PFASs have 
been demonstrated to induce lipid accumulation and perturbed lipid metabolism 




only study concerning the long-term effects of low-level exposure to common 
PFASs, in combination with dietary risk factors, and their potential role in the 
increasing incidence of NAFLD in the global population (Huck et al., 2018). Huck 
et. al. discovered that PFOS exhibited a surprising preventative effect against 
fatty liver in the presence of a high fat diet. The present study is the first to 
confirm this finding and delve further into the mechanistic drivers of diet-PFAS 
interactions.  
Understanding the potential health effects of PFAS members plays a vital role 
in guiding the federal regulations that determine health advisory levels in 
drinking water. Due to emerging toxicity data, the health advisory for PFOS in 
drinking water was lowered to 70 ppt in 2016 (US EPA, 2016). This health 
advisory level was derived from a no observable adverse effect level (NOAEL) 
dose of 0.1 mg/kg/day obtained from rodent toxicity studies evaluating the 
effects of PFOS on pup weight and mortality (Luebker, York, et al., 2005; 
Luebker, Case, et al., 2005). PFAS manufacturing companies, such as 3M, 
have voluntarily removed PFOS from manufacturing. However, PFNA may still 
legally be used as a PFAS replacement in manufacturing and consumer 
products (Kato et al., 2011). Despite the high potential for similar toxicity, PFNA 
remains unregulated at the federal level (Wang et al., 2015). Both PFOS and 
PFNA continue to be highly prevalent in humans, wildlife, and the environment 
today (Jian et al., 2018). This study investigates the potential consequences of 
chronic low-level exposure to PFASs in the diet-induced onset of NAFLD. 




sulfonic acid, PFOS and the carboxylic acid, PFNA while exploring the 
additional impact of diet interactions.   
 
MATERIALS AND METHODS 
Animals. The study was conducted at the University of Rhode Island in 
accordance with Institutional Animal Care and Use Committee (IACUC). 
C57BL6 mice were acquired from Jackson Labs (Bar Harbor, ME USA) at six-
weeks-old and were acclimated for two weeks prior to being weight paired and 
housed four per cage. The mice were housed in a temperature-controlled room 
and kept on a strict 12-hour dark/light cycle with access to food and water ad 
libitum. Body weights and food consumption were monitored weekly. Following 
12 weeks of diet administration, all mice were anesthetized using isoflurane and 
euthanized by cervical dislocation. Tissues were immediately harvested and 
snap frozen in liquid nitrogen. Gross liver weight was recorded prior to 
sectioning in 10% formalin for histology. The remaining liver was snap frozen 
for downstream analysis.   
 
PFOS and PFNA Dosing in Feed.  Mice were fed either a 10% kcal, low-fat diet 
(LFD, D12450B Research Diets, New Brunswick), or a matched 45% kcal, 
moderately high fat diet (HFD, D12451 Research Diets, New Brunswick). Mice 
were assigned to diet or diet containing either 0.0003% PFOS or 0.0003% 
PFNA and fed ad libitum for 12 weeks. PFOS (catalog # 33829-100mg) and 




Aldrich (St. Louis, MO, USA). The resulting treatment groups were as follows: 
low fat diet (LFD), high fat diet (HFD), LFD + PFOS (LPFOS), HFD + PFOS 
(HPFOS), LFD + PFNA (LPFNA), and HFD + PFNA (HPFNA) with n=8 per 
treatment group. The daily exposure to PFAS via diet was roughly 
~0.3mg/kg/day based on daily food consumption. In the current EPA health 
advisory document for PFOS, 0.3 mg/kg/day was considered a NOAEL dose for 
PFOS-induced developmental toxicity.  
 
Hepatic Lipid Isolation and Analysis.  Liver lipids were isolated from 
approximately 50 mg of liver tissue using the Folch chloroform-methanol 
extraction (Folch et al., 1957). Triacylglyceride (TAG) and total cholesterol, were 
measured using kits from Pointe Scientific (Ann Arbor, MI USA). Total non-
esterified free fatty acids (NEFA) were quantified using a kit from Wako 
Chemicals (Richmond, VA USA). Phospholipids were quantified using the 
EnzyChrom phospholipid colorimetric assay kit (BioAssay Systems, Hayward, 
CA, USA) according to kit instructions. Liver tissue sections were fixed in 10% 
buffered formalin prior to paraffin embedding. Paraffin sections (5 μm) were cut 
and stained with hematoxylin and eosin (H&E). Stains and scoring were 
conducted by Rutgers University Research Pathology Services (Piscataway, 
NJ).  The histopathological classification was made by a board-certified 






Quantification of PFAS Content in Liver.  LC-MS/MS was used to quantify 
hepatic PFAS concentrations and to further explore the effect of diet on internal 
distribution of PFASs to the liver. PFASs were isolated from liver using an 
adapted 3M method published by Chang et. al., 2017 (Chang et al., 2017). 
Roughly 100mg of tissue was homogenized in 4X LC-MS grade water spiked 
with C9 labeled PFNA (Cambridge Isotope Laboratories, Andover, MA, USA) 
and C4 labeled PFOS internal standards (Wellington Laboratories, Ontario, 
Canada). Of the homogenate, 250μL was transferred to a new tube containing 
10% 1N KOH and digested overnight. Following digestion, 100μL of sample was 
combined with 100μL 1N formic acid, 500μL 2N HCL, 500μL saturated 
ammonium sulfate, and 5mL LC-MS grade MTBE. The samples were shaken 
and then centrifuged for 5 min at 2500 x g. For each sample, 4.5mL of the 
organic layer was transferred to a fresh tube and evaporated overnight. The 
dried samples were re-suspended in 10mL acetonitrile: water and shaken for 
30 mins at room temperature. The samples were filtered through a 0.2μm 
syringe filter prior to injection on the instrument. The LC-MS/MS analysis was 
run in negative mode on a QTRAP® 4500 LC-MS/MS System. A Waters 
XBridge C18 (100mm x 4.6mm, 5μm) column was used. Sample injection 
volume was 10μL with a flow rate of 0.6mL/min. 
 
RNA Preparation and Transcriptomics. RNA was isolated from roughly 50mg of 
hepatic tissue using the Trizol method. The RNA was quantified and checked 




equal concentrations. RNA integrity was measured by Agilent Bioanalyzer using 
an Agilent RNA 6000 Nano kit. Only pure, intact RNA samples were used for 
downstream analysis, RIN score of ≥ 8. An Affymetrix mouse ST 2.0 global 
array (Affymetrix, Waltham, MA, USA) was conducted according to 
manufacturer protocols.  The array was conducted by the Genomics Core 
Facility at Brown University (Providence, RI). Raw .cel files were uploaded into 
the Transcriptome Analysis Console (TAC) version 4.0.1 (ThermoFisher, 
Waltham, MA USA). TAC software was used to conduct data normalization, 
quality control, and differential expression analysis (GEO accession number 
GSE138602). The data was filtered using the criteria of ≥ 1.5-fold change and 
p-value < 0.05. Pathway analysis was conducted using the Ingenuity Pathway 
Analysis (IPA) database from Qiagen (Krämer et al., 2014). The upstream 
analysis feature was used to predict upstream regulators. IPA’s comparison 
analysis tool was used to compare predicted activation and inhibition between 
treatment groups. In addition to the untargeted global array, a targeted 
assessment of key genes was conducted.  
 
QuantiGene Plex Targeted Gene Expression. Targeted gene expression 
analysis was conducted using a custom QuantiGene Luminex xMAP gene 
expression panel (ThermoFisher, Waltham, MA USA) using 0.5 ug of total RNA 
as input and according to the manufacturer’s protocol.  Analysis of the multiplex 
panel was performed according to the manufacturer’s protocols with mean 




Hercules, CA USA). Intensity values were normalized to housekeeper gene 
beta-actin (Actb) and converted to fold change relative to the control. Hepatic 
genes involved in inflammation, lipid uptake, lipid metabolism, and lipid 
regulation were analyzed. Genes of interest in the liver included Acaca, Acot2, 
Ccl2, Cd36, Cpt1a, Cpt1b, Csf2ra, Cyp4a14, Ehhadh, Gstm3, Fabp1, Cidea, 
Fabp4, Fas, Gapdh, Gclc, Gpam, Gusb, Hmgsc1, IL6, Lpl, Nrf2, Nqo1, Pparα, 
Pparγ, Scd1, Slc27a1, Sod1, Srebf1, Tnfα, Actb, Hprt, Ppia, and Ppib 
(Supplemental Table 1).  
 
Protein Digestions and SWATH-MS Proteomics. Stock protein samples (5 
mg/mL) were diluted to 2.5 mg/mL. Protein (200 µg) was spiked with 2 µg BSA 
and denatured with 20 µL dithiothreitol (DTT, 100 mM) at 95°C for 15 min in a 
shaking water bath (100 rpm). After denaturation, samples were alkylated in the 
dark with 20 µL indole-3-acetic acid (IAA, 200 mM) for 30 min at room 
temperature. Subsequently, 40 µL of 50 mM ammonium bicarbonate was added 
to each sample was pH was confirmed to be alkaline. Further, TPCK-treated 
trypsin (10 µg) was added to samples at a ratio of 1:20 (trypsin:protein) and 150 
µL of the resulting solution was transferred into digestion tube (PCT 
MicroTubes, Pressure Biosciences Inc., Easton, MA). The barocycler was run 
at 50°C, for 90 cycles with 60 sec per pressure-cycle (50 sec high pressure, 10 
sec ambient pressure, 25 kpsi). Further, to 145 µL of digested peptide sample, 
5 µL of ACN (1:1, v/v containing 5% formic acid) was added to acidify the 




participate and 125 µL supernatant was collected (10000 rpm for 5 min at 10°C). 
Subsequently, twenty microliters of the resulting peptide solution was injected 
into the analytical column and samples were analyzed using LC-MS/MS. 
SWATH-DIA proteomics was conducted as previously published(Jamwal et al., 
2017) The proteomics was run on an Acquity UHPLC HClass system (Waters 
Corp., Milford, MA, USA) coupled to a SCIEX 5600 TripleTOF mass 
spectrometer (SCIEX, Concord, Canada). The method used a run time of 60 
min at 100μL/min and a linear gradient. Global protein changes were assessed 
using MaxQuant (Tyanova, Temu, and Cox, 2016) and Perseus (Tyanova, 
Temu, Sinitcyn, et al., 2016). Targeted data analysis was conducted on the 
opensource software Skyline (MacLean et al., 2010) (MacCoss Lab Software) 
and normalized to peptide concentration and BSA spiked control. The mass 
spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium via the PRIDE partner repository with the dataset identifier 
PXD015977. 
 
Statistical Analysis.  Body weight, tissue weight, and hepatic PFAS 
concentrations are shown as mean ± standard error (SEM). Unless otherwise 
indicated, data was analyzed using one-way analysis of variance (ANOVA) 
followed by Fisher’s LSD test for multiple comparisons where p < 0.05 was 
denoted as statistically significant. Calculations were performed using 






PFOS and PFNA exert differential effects on white adipose, liver, and body 
weight  
Mice were weight matched prior to assignment to treatment group. Body, liver, 
and WAT weight comparisons between low fat diet (LFD) mice and high fat diet 
(HFD) fed mice showed an increase of approximately 41%, 36%, and 144% 
respectively (Table 1). Interestingly, both PFOS and PFNA caused significant 
modulation of tissue and body weights but the effects differed based on the 
compound structure. For example, the LPFOS group produced a 44% increase 
in WAT weight while LPFNA treatment resulted in a 44% decrease relative to 
the LFD controls. Furthermore, PFNA produced a dramatic change in liver 
weight with increases of 155% and 73%, relative to the LFD and HFD control, 
whereas PFOS only increased liver weight by 18% and 13% respectively.  
Lastly, we observed a significant discrepancy in weight gain between the PFOS 
and PFNA treated mice within both diets, with PFNA treated mice gaining 
significantly less body weight relative to their PFOS treated counterparts. 
 
Dietary fat has a significant impact on PFAS modulation of hepatic lipid 
content  
An excess of dietary fatty acids within the liver can augment formation of hepatic 
lipid droplets and trigger the onset of hepatic steatosis. To explore the potential 
interaction of dietary fat with PFOS and PFNA modulation of hepatic lipid 




phospholipids were quantified (Figure 1A). Within HFD, PFNA decreased 
triglyceride content by 28.4%, relative to the HFD control. Within the LFD, PFOS 
and PFNA caused significant decreases in hepatic phospholipid content, by 
34.3% and 15.6%. This effect was conserved within the HFD with reduction by 
31.6% and 33.6%, respectively.  To visualize hepatic steatosis, liver sections 
were collected at necropsy and scored by a board-certified pathologist for lipid 
accumulation (Table 2).                                                                                                                                         
Representative images using hematoxylin and eosin (H&E) staining for each 
treatment group are shown in Figure 1C. Arrows highlight hepatic lipid droplets 
indicative of steatosis. The HFD controls exhibited clear macrovesicular 
steatosis and overall significantly higher scoring for lipid accumulation when 
compared to the LFD control. The LFD controls exhibited healthy liver pathology 
with 0% of the mice achieving a lipid accumulation score greater than or equal 
to 2. Within the LFD fed groups PFOS and PFNA caused an expected increase 
in liver lipid accumulation, with 38% and 50% scoring ≥2. The observed increase 
in microvesicular steatosis was significant within the LPFNA group. However, 
within the high fat diet PFNA exposure resulted in significantly lower scoring for 
liver lipid accumulation when compared to HFD control. Out of 8 mice, 100% of 
the HFD controls scored ≥2, whereas only 86% for PFOS and 75% for PFNA. 
Visually, there is a clear reduction in macrovesicular steatosis within the HPFOS 





PFOS and PFNA modulation of the hepatic transcriptome is significantly 
affected by the PFAS chemical functional head group. 
Hepatic gene expression was explored to determine the consequence of PFOS 
and PFNA structure, differing by functional head group, in the liver (Figure 2). 
Hepatic RNA was prepared for an untargeted transcriptomic array, detecting 
34,472 total genes. Between 1,303 and 1,424 hepatic genes were significantly 
modulated (p<0.05) by PFOS or PFNA at least 1.5-fold change. To explore the 
top genes impacted by PFAS exposure, the top 5 global genes modulated by 
diet-PFAS treatment were identified (Table 3). Cyp2b10, a gene involved in the 
oxidation of fatty acids, steroids, and xenobiotics, was the top impacted gene in 
3 out of the 4 PFAS groups: LFD vs LPFOS (59.1-fold), LFD vs LPFNA (27.0-
fold), and HFD vs HPFOS (33.5-fold). Cidea, a gene involved in lipid droplet 
enlargement, was heavily modulated by the HPFNA group with a measured 
global fold change of 88.1 relative to the HFD control. While the total number of 
genes modulated by PFNA or PFOS are similar, the transcriptomic signatures, 
as measured by overlap between genes impacted, were remarkably unique. 
Moreover, scatter plots directly comparing the log2 of the average signal 
intensity for PFOS vs PFNA highlight the structure specific modulation in red 
and green.  
Within the LFD, structure specific effects were observed. Compared to the LFD, 
LPFNA and LPFOS modulated a total of 1405 and 1424 hepatic genes 
respectively. Out of the total number of differentially expressed genes, only 799 




both shared and unique genes modulated by PFOS and PFNA within in the liver. 
The top genes induced or repressed within each comparison are summarized 
within each box. Figure 2B shows a direct comparison of the average signal 
(log2) of LPFNA to LPFOS revealing 260 differentially expressed genes. 
Compared to LPFOS, LPFNA upregulated RNA associated genes Ddx3y, Mt-
tq, and Supt4b by 4.7, 3.4, and 2.5-fold. Overall, LPFNA suppressed 
keratinization and immune response related genes while upregulating genes 
involved in RNA processing and transcription when compared to LPFOS.  
Structure dependent effects on hepatic gene expression were more pronounced 
within the HFD treatment groups. Out of 1,368 and 1,303 genes modulated by 
HFD vs HPFNA and HFD vs HPFOS, only 647 of those genes were conserved 
between the treatment groups (Figure 2C). Roughly half of the genes modulated 
by PFOS or PFNA were unique to the compound’s functional head group, 656 
and 721 respectively. Figure 2D depicts 764 differentially expressed genes 
when comparing HPFNA to HPFOS directly.  Cidea was the top differentially 
expressed gene, induced 73.7-fold times higher within the HPFNA treatment 
group compared to HPFOS. Furthermore, HPFNA caused relative induction of 
Fabp3, a known fatty acid and potential PFAS uptake transporter, by 52.3-fold 
and Spltc3, involved in the rate limiting step of sphingolipid biosynthesis, by 
34.5-fold. In contrast, HPFNA reduced expression of Hsd3b5, involved in the 
biosynthesis of active steroids, by 21.4-fold in comparison to HPFOS. In 
addition, HPFNA reduced the expression of Oatp1a1 and Oatp1a4, known 




HPFOS. These robust changes in expression within the same base diets 
confirms a significant and PFAS specific alteration to the hepatic transcriptome, 
attributable to the functional head group. 
 
 PFOS and PFNA modulation of the hepatic transcriptome is significantly 
impacted by dietary fat. 
A notable diet effect was observed on hepatic transcriptomic expression. When 
comparing the PFOS impacted genes within each diet only 617, less than half 
of the total differentially expressed genes, were shared between LPFOS and 
HPFOS compared to control diet (Figure 3A). When directly comparing HPFOS 
to LPFOS gene expression, 824 differentially expressed genes were identified 
(Figure 3B). Cidea, a gene involved in lipid droplet enlargement, was the top 
differentially expressed gene, induced 73.7-fold times higher within the HPFOS 
treatment group compared to LPFOS. Furthermore, HPFOS caused relative 
induction of Fabp3, a known fatty acid and potential PFAS uptake transporter, 
by 52.3-fold and Spltc3, involved in the rate limiting step of sphingolipid 
biosynthesis, by 34.5-fold. In contrast, HPFOS reduced expression of Hsd3b5, 
involved in the biosynthesis of active steroids, by 21.4-fold in comparison to 
LPFOS. In addition, HPFOS reduced the expression of Oatp1a1 and Oatp1a4, 
known PFOS uptake transporter genes, by 16.6 and 11.3-fold relative to 
LPFOS. Overall, diet modulated PFOS induced expression of genes involved in 





The pronounced diet effect observed with PFOS exposure was conserved in 
the PFNA treated groups. LFD vs LPFNA modulated 824, while HFD vs HPFNA 
impacted 787 genes unique to the diet. As measured by scatter plot, the direct 
comparison of LPFNA to HPFNA based on the log2 of the average signal 
intensity yielded 279 differentially expressed genes. Compared to LPFNA, 
HPFNA downregulated RNA genes, Snord92 and Ddx37, by 4.4-fold and 
metalloprotease, Adam11 by 2.2-fold. In contrast, HPFNA caused relative 
induction of olfactory related genes, Obp2a and Vmn2r109, and the RNA gene, 
Traj58, by 4.5, 3.0, and 2.4-fold. Based on the expression data, it is clear that 
diet exerted a significant influence on PFAS modulation of hepatic 
transcriptome.  
 
PFNA is a potent inducer of lipid metabolism, transport, and accumulation 
genes.  
Targeted gene expression of key genes involved in lipid metabolism, synthesis, 
transport, and oxidative stress was measured (Figure 4). The targeted panel of 
hepatic genes, names, and functions is further described in Supplemental Table 
1. Within the targeted data compound and diet specific effects between PFOS 
and PFNA were observed. In the case of Acaca, PFOS caused a 0.8-fold 
reduction in expression yet PFNA caused 1.7-fold induction of the same gene. 
(Figure 2B), we observed a clear diet effect for genes such as Lpl and Cidea. 
Within the LPFOS treatment group a 3.3-fold induction of Lpl was observed, 




LPFOS group, despite no observed diet induction within the HFD controls. 
Likewise, Cidea showed diet specific effects in both PFOS and PFNA treated 
mice. Within the LPFOS group, there was no significant induction of Cidea, 
however the HPFOS group experienced an 8.5-fold induction in Cidea. Both 
PFOS and PFNA affected lipid homeostasis and oxidative stress related genes 
and pathways related to perturbed hepatic lipid content on both a targeted and 
global scale. Compared to PFOS, PFNA exposure produced 10 to 100-fold 
stronger induction of several genes including Acot2, Cpt1b, and Cidea when 
administered at the same dose. Overall, PFNA caused stronger induction of 
hepatic genes relative to PFOS.  
 
Diet and PFAS interactions cause differential activation of upstream 
transcriptional drivers and downstream pathways that can modulate the 
onset and progression of NAFLD.  
Looking further into the mechanistic function of the untargeted hepatic genes 
perturbed by PFAS exposure, upstream pathway regulators were assessed for 
potential activation or inhibition (Figure 4). Both PFOS and PFNA significantly 
modulated pathways regulated by Ppar, Pxr, Car, Zbtb, and Ahr. PFOS and 
PFNA selectively modulated Pml whereas PFOS exerted no effect on this 
pathway. Interestingly, HPFOS and HPFNA mediated stronger induction of 
Ppar𝛼𝛼 compared to the HFD controls as well as LPFOS and LPFNA, 
respectively. Ppar𝛼𝛼 is a key upstream regulator for lipid homeostasis in the liver 




hepatic lipid outcomes. A diet-specific response was also observed in the 
coactivator, Ncoa2. Within the HFD, PFOS and PFNA exposure suppressed 
signaling of Ncoa2, whereas in the HFD control and LPFOS, an increased z-
score was observed. The data suggest that PFNA and PFOS preferentially 
activate or enhance the activity of key upstream pathway drivers, such as Ppar𝛼𝛼, 
when combined with a HFD. In addition, activation of Nrf2 was observed only 
within the PFNA groups, suggesting structure specific activation. The summary 
of key transcriptional drivers in response to PFAS exposure and their impact on 
NAFLD progression is summarized in Table 4.  
Downstream pathway outcomes were predicted using the core analysis feature 
and outcomes were compared using comparison analysis within IPA (Figure 5). 
Pathways were assigned a z-score indicating predicated activation or inhibition 
based on the number of overlapping differentially expressed and direction of 
expression for each pathway. HPFNA exhibited the highest degree of 
downstream activity activating competing pathways related to the onset of fatty 
liver. HPFNA activated genes involved in lipid accumulation, such as fatty acid 
and lipid synthesis, as well as lipid metabolism pathways, including beta 
oxidation of fatty acids. HPFOS increased glucose and carbohydrate synthesis 
pathways and modulated the activation and quantity of immune cells. LPFOS 
and LPFNA led to increased synthesis of fatty acids. In addition, LPFNA 
activated the competing pathways of fatty acid uptake and fatty acid 
metabolism. The upstream drivers and downstream pathways modulated by 




lipid accumulation, making the key drivers difficult to interpret. Overall, diet and 
PFAS functional head group exerted influence on both upstream transcriptional 
drivers and downstream pathway outcomes.  
 
Diet and structure induced alterations in the transcriptomic signatures of 
PFOS and PFNA are conserved at the protein level. 
Proteomics was performed on mouse hepatic tissue to derive the expression of 
>300 hepatic proteins. The global analysis of the liver proteome supports the 
diet and compound effects observed in the transcriptomic data. A PCA plot was 
generated to visualize changes in the global liver proteome (Figure 7). Distinct 
groupings can be observed between treatment groups. Both diet and the PFAS 
compound caused distinct shifts in the proteomic signature of the liver. 
Interestingly, the federally unregulated PFNA showed a drastic shift in grouping 
compared to both PFOS and dietary controls. In Figure 8, the total number of 
differentially expressed proteins out of total proteins detected can be found 
within the box next to each comparison. Again, both diet and structure 
dependent effects on expression were observed. For example, LPFNA 
significantly impacted the expression of 197 out of ~300 proteins detected while 
LPFOS modulated 65. LPFNA and LPFOS shared 46 proteins, while LPFOS 
retained 19 and LPFNA 151 unique changes. 
To confirm the global changes observed, targeted quantification of relevant lipid 
and oxidative stress related molecules was performed using open source 




potency of PFNA can be clearly observed at the protein level in the expression 
of fatty acid metabolizing, cytochrome P450s, and antioxidant proteins. For the 
cytochrome P450s, PFOS exhibited stronger induction for Cyp2c enzymes 
including, Cyp2c50 and Cyp2c37. However, PFNA showed more potent 
induction for Cyp4a enzymes, Cyp4a12 and Cyp4a14. Lastly, we observed that 
the relative induction of gene and protein expression was conserved for many 
of the overlapping gene and protein targets such as Ehhdah and Cyp4a14. In 
conclusion, both PFOS and PFNA significantly modulated the liver proteome 
and potential metabolic function at an exposure relevant dose. 
 
Diet specific modulation of liver pathology in the presence of PFAS could 
be attributed to altered expression of PFAS uptake transporters. 
Diet exerted a dramatic influence on the resulting liver pathology. A potential 
mechanism to explain the paradoxical effect of PFAS in combination with high 
fat diet on the onset of fatty liver disease is proposed in Figure 10. PFASs have 
low passive permeability and a high (≥ 400) molecular weight. PFAS uptake 
into the liver and reabsorption from the kidney is known to be driven by a class 
of transporters called organic anion transporter proteins (Oatps). In the liver, 
there are four major Oatps that mediate hepatic uptake from the bloodstream: 
Oatp1a1, Oatp1a4, Oatp1b2, and Oatp2b1. In the HFD treated groups, Oatp 
transporter expression was significantly reduced by PFAS exposure (Figure 
10A). To examine if diet influences the uptake of PFOS and PFNA into the liver, 




(Figure 13B). HFD feeding caused a significant decrease in hepatic 
concentration of PFOS and PFNA when compared to LFD feeding. In addition, 
PFNA achieved significantly higher hepatic concentrations than PFOS within 
both the LFD and HFD treated groups when administered at the same dose. 
When taken together, these findings suggest that the high fat diet reduced 
PFAS accumulation within the liver via decreased uptake transporter 
expression.  
 PFASs are known to interact with not only Oatps but also with fatty acid binding 
proteins (Fabps) for transporter mediated uptake.  In Figure 6, we observed that 
the expression of fatty acid uptake transporters Fabp1, Fabp4, Cd36, and 
Slc27a1 was induced by PFAS within both diets.  In Figure 4, a notable increase 
in Ppar𝛼𝛼 activity within the HFD + PFAS groups can be observed. Ppar𝛼𝛼 
activation leads to the downregulation of Oatps. This diet specific 
downregulation coupled with an elevated influx of dietary fatty acids from the 
HFD into the serum may lead to increased competition between PFASs and 
FFAs for hepatic uptake. This competitive uptake could lead to a decrease in 
both lipid and PFAS accumulation in the liver.   
 
DISCUSSION 
The majority of studies examining PFAS induced hepatic steatosis utilize 
relatively high doses of PFAS, acute exposure windows, and a standard diet 
(Wan et al., 2012; Kudo et al., 2006; Bagley et al., 2017; Curran et al., 2008b). 




liver when administered with a lean standard mouse chow (Armstrong and Guo, 
2019). However, the mechanism of this toxicant associated fatty liver disease 
(TAFLD) is still poorly understood. The current theories include PFAS induced 
choline deficiency (Zhang et al., 2016), impaired mitochondrial function (Quist 
et al., 2015; Yao et al., 2016), and impaired lipid export via VLDL (Bijland et al., 
2011; Wang et al., 2014). PFAS exposure is lifelong and there is a need to better 
understand the potential hepatotoxicity of PFAS under chronic exposure to 
environmentally relevant doses. Moreover, the largest risk factor for NAFLD is 
metabolic syndrome, often initiated by poor diet. In order to better explore the 
ability of PFAS to augment NAFLD risk, the experimental design must take into 
account the most common risk factor for fatty liver, diet induced metabolic 
syndrome. 
Only one paper published to date examines a direct sub-chronic NOAEL 
exposure to PFAS, in combination with dietary fat on the development of hepatic 
steatosis. According to Huck et al., high fat diet feeding in combination with 
0.0001% PFOS (~0.1mg/kg/day) resulted in a paradoxical effect against hepatic 
lipid accumulation (Huck et al., 2018). Currently, there is no study to date that 
has confirmed this contradictory finding or further explored the potential 
mechanistic cause. Using a NOAEL dose of 0.0003% PFAS in diet 
(~0.3mg/kg/day), this study confirms that co-administration with a high-fat diet 
can attenuate low-dose PFOS induced hepatic lipid accumulation. In addition, 
this effect was observed using a carboxylic acid containing PFAS member, 




on hepatic PFAS accumulation and utilizes ‘omics techniques to uncover the 
mechanistic drivers of the diet specific response to PFAS exposure.  
In the present study, we observed significant PFAS effects on mouse body, 
white adipose tissue, and liver weight. PFAS are well-known to reduce body and 
white adipose tissue weight, while inducing liver weight at higher doses in 
rodents. However, the dose administered in this study was too low to observe 
significant PFOS effects on these endpoints. In a study of PFOS exposure to 
dams at 0.3mg/kg/day there was similarly no effect on gross weight outcomes, 
whereas significant changes were observed at the high dose of 3mg/kg/day 
(Wan et al., 2014). Despite administration at the same low dose, PFNA 
exposure resulted in significant modulation to body, WAT, and hepatic weights. 
PFNA has been previously reported to cause marked hepatomegaly at higher 
doses, more so than structurally similar perfluorinated carboxylic acids (PFCAs) 
(Kudo et al., 2006). However, the potency of PFNA on gross body and tissue 
weights was surprising given the use of an environmentally relevant dose.  
PFAS are well known to cause dyslipidemia in rodents as well as humans. In 
rodents PFAS are known to cause accumulation of hepatic TAGs, increased 
hepatic lipid deposition, and hypocholesterolemia. Interestingly, we observed 
significant attenuation of hepatic phospholipid content by PFOS and PFNA 
within the LFD and HFD. Phospholipids are known to have a hypolipidemic 
effect within the liver and have even been used to attenuate fatty liver disease 
(Gundermann et al., 2016). The implication of PFAS reduction in hepatic 




explored. Phospholipids are known to predict PFAS partitioning and the ability 
of phospholipids to bind to PFASs has been confirmed (Dassuncao et al., 2019; 
Sanchez Garcia et al., 2018). Phospholipids act as a surfactant to stabilize lipid 
droplets, are the major constituent of cell membranes, and aid in vesicle 
formation for lipid export. Moreover, an atypical reduction in TAG content was 
produced by PFNA and PFOS supplementation within the HFD. This result 
supports the histopathology showing significant reduction in hepatic lipid 
accumulation with co-administration of PFAS and a high fat diet. This is the 
second study to report that a sub-chronic environmentally relevant dose of 
PFOS attenuates high fat diet induced hepatic steatosis. Furthermore, this is 
the first paper to demonstrate this effect using a PFCA. Our group went further 
to quantify the hepatic concentration of PFASs within each treatment group and 
characterize their biochemical signatures. Interestingly, we observed significant 
reduction in hepatic PFAS concentration with administration of a high fat diet. 
There is developmental study that reports a high fat diet significantly increased 
hepatic PFAS concentrations in pups with perinatal exposure to PFASs via 
dams (Wang et al., 2014).The present work uncovers a novel finding, with direct 
PFAS exposure diet modulates the partitioning or excretion of PFASs to 
decrease deposition within the liver. Lastly, we confirmed previous reports that 
PFNA has more bioaccumulative potential within the murine liver when 
compared to the sulfonic acid, PFOS.  
The mechanism of diet-PFAS interactions has not been adequately explored. 




response is differential regulation of Ppar𝛾𝛾 and its down-stream target, Cd36. 
However, in the current study no diet specific response in Ppar𝛾𝛾 nor the fatty 
acid uptake transporter, Cd36, was observed. This finding was confirmed by 
western blot (Supplemental figure 2). PFASs are generally accepted to be 
robust Ppar𝛼𝛼 inducers and the findings presented here confirm this. Overall, 
PFNA was a more potent inducer of Ppar𝛼𝛼 and the overall transcriptome when 
compared to PFOS. The hepatic concentrations of HPFNA and LPFOS were 
very similar suggesting that increased transcriptional and protein level 
expression induced by PFNA is not entirely dependent on the increased hepatic 
deposition. The increased hepatic uptake could be in part due to the PFNA 
specific induction of Fabp4, a potential PFAS uptake transporter. This potent 
effect on both gene and protein level expression suggests that PFNA may 
produce hepatotoxic outcomes at lower doses than PFOS and therefore may 
require stricter regulation. Moreover, diet imposed significant influence on the 
overall hepatic signatures for both PFOS and PFNA. Ppar𝛼𝛼 induces the 
metabolic breakdown of fatty acids and is known to have a protective effect 
against the onset of NAFLD. PFASs has been shown to reduce the expression 
of Oatps via Ppar𝛼𝛼 mediated suppression (Cheng and Klaassen, 2008). Oatps 
are known transporters of PFASs and have been demonstrated to mediate 
PFAS deposition and reabsorption. Furthermore, both PFASs and fatty acids 
are known to interact with Fabp transporters for hepatic uptake. The decreased 
expression of a primary PFAS transporter coupled with increasing competition 




mechanism for the underlying cause of the diminished hepatic deposition of 
both lipid and PFASs within the high fat diet treatment groups. 
 
CONCLUSIONS 
Using a diet-induced obesity rodent model, we sought to explore the potential 
role of diet in PFOS and PFNA induced fatty liver disease. Despite the lack of 
federal regulation, PFNA was significantly more potent than PFOS in altering 
hepatic molecular pathways and exhibited increased hepatic deposition. These 
findings suggest that PFNA may require stricter regulation than PFOS despite 
its structural similarity. Importantly, dietary fat exhibits a prominent influence on 
PFAS hepatic accumulation, pathology, and biochemical pathways. This effect 
may be caused by Ppar𝛼𝛼 mediated suppression of PFASs uptake transporters, 
Oatps. Further studies are warranted to further confirm and explore PFAS-diet 
interactions and their potential implications in assessing internal exposure and 
risk in human populations. 
 
CONFLICT OF INTEREST 
The authors declare no financial conflict of interest. 
 
FUNDING 
This work was supported by NIH grants 1R15ES025404-01 and P42ES027706.  
This material is based upon work conducted at University of Rhode Island at a 




Center, and the Molecular Characterization Facility, supported in part by the 
National Science Foundation EPSCoR Coopoerative Agreement # OIA-
1655221. The transcriptomic array was conducted at the Brown University 
Genomics Facility with partial support from the National Institutes of Health 
(NIGMS grant Number P30GM103410, NCRR grant Numbers P30RR031153, 
P20RR018728 and S10RR02763), National Science Foundation (EPSCoR 
grant No 0554548), Lifespan Rhode Island Hospital, and the Division of Biology 
and Medicine, Brown University. 
 
REFERENCES 
Armstrong, L.E. and Guo, G.L. (2019) Understanding Environmental 
Contaminants’ Direct Effects on Non-alcoholic Fatty Liver Disease 
Progression. Curr Environ Health Rep, 6, 95–104. 
Bagley, B.D. et al. (2017) Perfluorooctane Sulfonate-Induced Hepatic 
Steatosis in Male Sprague Dawley Rats Is Not Attenuated by Dietary Choline 
Supplementation. Toxicol. Sci., 160, 284–298. 
Ballesteros, V. et al. (2017) Exposure to perfluoroalkyl substances and thyroid 
function in pregnant women and children: A systematic review of 
epidemiologic studies. Environment International, 99, 15–28. 
Barber, J.L. et al. (2007) Analysis of per- and polyfluorinated alkyl substances 




Bijland, S. et al. (2011) Perfluoroalkyl sulfonates cause alkyl chain length-
dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein 
production in APOE*3-Leiden CETP mice. Toxicol. Sci., 123, 290–303. 
Bjork, J.A. et al. (2011) Multiplicity of nuclear receptor activation by PFOA and 
PFOS in primary human and rodent hepatocytes. Toxicology, 288, 8–17. 
Buck, R.C. et al. (2011) Perfluoroalkyl and polyfluoroalkyl substances in the 
environment: terminology, classification, and origins. Integr Environ Assess 
Manag, 7, 513–541. 
Calafat, A.M. et al. (2007) Polyfluoroalkyl Chemicals in the U.S. Population: 
Data from the National Health and Nutrition Examination Survey (NHANES) 
2003–2004 and Comparisons with NHANES 1999–2000. Environ Health 
Perspect, 115, 1596–1602. 
Chang, S. et al. (2017) Evaluation of Serum Lipid, Thyroid, and Hepatic 
Clinical Chemistries in Association With Serum Perfluorooctanesulfonate 
(PFOS) in Cynomolgus Monkeys After Oral Dosing With Potassium PFOS. 
Toxicol Sci, 156, 387–401. 
Cheng, X. and Klaassen, C.D. (2008) Critical Role of PPAR-α in 
Perfluorooctanoic Acid– and Perfluorodecanoic Acid–Induced Downregulation 
of Oatp Uptake Transporters in Mouse Livers. Toxicol Sci, 106, 37–45. 
Chowdhry, S. et al. (2010) Loss of Nrf2 markedly exacerbates nonalcoholic 




Curran, I. et al. (2008a) Altered fatty acid homeostasis and related toxicologic 
sequelae in rats exposed to dietary potassium perfluorooctanesulfonate 
(PFOS). J. Toxicol. Environ. Health Part A, 71, 1526–1541. 
Curran, I. et al. (2008b) Altered Fatty Acid Homeostasis and Related 
Toxicologic Sequelae in Rats Exposed to Dietary Potassium 
Perfluorooctanesulfonate (PFOS). Journal of Toxicology and Environmental 
Health, Part A, 71, 1526–1541. 
Das, K.P. et al. (2017) Perfluoroalkyl acids-induced liver steatosis: Effects on 
genes controlling lipid homeostasis. Toxicology, 378, 37–52. 
Dassuncao, C. et al. (2019) Phospholipid Levels Predict the Tissue 
Distribution of Poly- and Perfluoroalkyl Substances in a Marine Mammal. 
Environmental Science & Technology Letters. 
Diagnosis of NAFLD & NASH | NIDDK National Institute of Diabetes and 
Digestive and Kidney Diseases. 
Duseja, A. and Chalasani, N. (2013) Epidemiology and risk factors of 
nonalcoholic fatty liver disease (NAFLD). Hepatol Int, 7 Suppl 2, 755–764. 
Effendi, K. et al. (2016) Pathological Findings of NASH and NAFLD. Hepatol 
Res, n/a-n/a. 
El-Agroudy, N.N. et al. (2019) Are Lifestyle Therapies Effective for NAFLD 




Folch, J. et al. (1957) A simple method for the isolation and purification of total 
lipides from animal tissues. J. Biol. Chem., 226, 497–509. 
Grandjean, P. et al. (2012) Serum vaccine antibody concentrations in children 
exposed to perfluorinated compounds. JAMA, 307, 391–397. 
Gundermann, K.-J. et al. (2016) Essential phospholipids in fatty liver: a 
scientific update. Clin Exp Gastroenterol, 9, 105–117. 
Hu, X.C. et al. (2016) Detection of Poly- and Perfluoroalkyl Substances 
(PFASs) in U.S. Drinking Water Linked to Industrial Sites, Military Fire Training 
Areas, and Wastewater Treatment Plants. Environ. Sci. Technol. Lett., 3, 344–
350. 
Huck, I. et al. (2018) Paradoxical Protective Effect of Perfluorooctanesulfonic 
Acid Against High-Fat Diet-Induced Hepatic Steatosis in Mice. Int. J. Toxicol., 
37, 383–392. 
Jamwal, R. et al. (2017) Multiplex and Label-Free Relative Quantification 
Approach for Studying Protein Abundance of Drug Metabolizing Enzymes in 
Human Liver Microsomes Using SWATH-MS. J. Proteome Res., 16, 4134–
4143. 
Jian, J.-M. et al. (2018) A short review on human exposure to and tissue 
distribution of per- and polyfluoroalkyl substances (PFASs). Sci. Total 




Kato, K. et al. (2011) Trends in exposure to polyfluoroalkyl chemicals in the 
U.S. Population: 1999-2008. Environ. Sci. Technol., 45, 8037–8045. 
Kim, S.M. et al. (2017) Novel PPARα agonist MHY553 alleviates hepatic 
steatosis by increasing fatty acid oxidation and decreasing inflammation during 
aging. Oncotarget, 8, 46273–46285. 
Krämer, A. et al. (2014) Causal analysis approaches in Ingenuity Pathway 
Analysis. Bioinformatics, 30, 523–530. 
Kudo, N. et al. (2006) Responses of the liver to perfluorinated fatty acids with 
different carbon chain length in male and female mice:in relation to induction 
of hepatomegaly, peroxisomal beta-oxidation and microsomal 1-
acylglycerophosphocholine acyltransferase. Biol. Pharm. Bull., 29, 1952–1957. 
Liu, G. et al. (2017) Regulation of hepatic lipogenesis by the zinc finger protein 
Zbtb20. Nat Commun, 8. 
Liver Disease Statistics - American Liver Foundation. 
Luebker, D.J., York, R.G., et al. (2005) Neonatal mortality from in utero 
exposure to perfluorooctanesulfonate (PFOS) in Sprague-Dawley rats: dose-
response, and biochemical and pharamacokinetic parameters. Toxicology, 
215, 149–169. 
Luebker, D.J., Case, M.T., et al. (2005) Two-generation reproduction and 





MacLean, B. et al. (2010) Skyline: an open source document editor for 
creating and analyzing targeted proteomics experiments. Bioinformatics, 26, 
966–968. 
Nelson, J.W. et al. (2010) Exposure to Polyfluoroalkyl Chemicals and 
Cholesterol, Body Weight, and Insulin Resistance in the General U.S. 
Population. Environ Health Perspect, 118, 197–202. 
Nicole, W. (2013) PFOA and Cancer in a Highly Exposed Community: New 
Findings from the C8 Science Panel. Environ Health Perspect, 121, A340. 
Olsen, G.W. et al. (2007) Half-Life of Serum Elimination of 
Perfluorooctanesulfonate,Perfluorohexanesulfonate, and Perfluorooctanoate 
in Retired Fluorochemical Production Workers. Environ Health Perspect, 115, 
1298–1305. 
Olsen, G.W. et al. (2017) Per- and polyfluoroalkyl substances (PFAS) in 
American Red Cross adult blood donors, 2000–2015. Environmental 
Research, 157, 87–95. 
Quist, E.M. et al. (2015) Hepatic Mitochondrial Alteration in CD-1 Mice 
Associated with Prenatal Exposures to Low Doses of Perfluorooctanoic Acid 
(PFOA). Toxicol Pathol, 43, 546–557. 
Rosen, M.B. et al. (2013) Evaluation of perfluoroalkyl acid activity using 




Salihovic, S. et al. (2018) Changes in markers of liver function in relation to 
changes in perfluoroalkyl substances - A longitudinal study. Environ Int, 117, 
196–203. 
Sanchez Garcia, D. et al. (2018) Cellular accumulation and lipid binding of 
perfluorinated alkylated substances (PFASs) – A comparison with 
lysosomotropic drugs. Chemico-Biological Interactions, 281, 1–10. 
Seacat, A.M. et al. (2002) Subchronic Toxicity Studies on 
Perfluorooctanesulfonate Potassium Salt in Cynomolgus Monkeys. Toxicol 
Sci, 68, 249–264. 
Shoaff, J. et al. (2018) Prenatal exposure to perfluoroalkyl substances: Infant 
birth weight and early life growth. Environmental Epidemiology, 2, e010. 
Tyanova, S., Temu, T., and Cox, J. (2016) The MaxQuant computational 
platform for mass spectrometry-based shotgun proteomics. Nature Protocols, 
11, 2301–2319. 
Tyanova, S., Temu, T., Sinitcyn, P., et al. (2016) The Perseus computational 
platform for comprehensive analysis of (prote)omics data. Nature Methods, 13, 
731. 
US EPA, O. (2016) Drinking Water Health Advisories for PFOA and PFOS. US 
EPA. 
Wada, T. et al. (2016) Aryl Hydrocarbon Receptor Plays Protective Roles 




Lipotoxicity via Direct Transcriptional Regulation of Socs3 Gene Expression. J. 
Biol. Chem., 291, 7004–7016. 
Wan, H.T. et al. (2014) Perinatal Exposure to Perfluorooctane Sulfonate 
Affects Glucose Metabolism in Adult Offspring. PLoS One, 9. 
Wan, H.T. et al. (2012) PFOS-induced hepatic steatosis, the mechanistic 
actions on β-oxidation and lipid transport. Biochim. Biophys. Acta, 1820, 
1092–1101. 
Wang, J. et al. (2015) Integrated proteomic and miRNA transcriptional analysis 
reveals the hepatotoxicity mechanism of PFNA exposure in mice. J. Proteome 
Res., 14, 330–341. 
Wang, L. et al. (2014) PFOS induced lipid metabolism disturbances in BALB/c 
mice through inhibition of low density lipoproteins excretion. Scientific Reports, 
4, 4582. 
Winkens, K. et al. (2018) Perfluoroalkyl acids and their precursors in floor dust 
of children’s bedrooms - Implications for indoor exposure. Environ Int, 119, 
493–502. 
Yamazaki, Y. et al. (2007) The role of the nuclear receptor constitutive 





Yao, X. et al. (2016) Perfluorooctane Sulfonate Induces Autophagy-
Dependent Apoptosis through Spinster 1-Mediated lysosomal-Mitochondrial 
Axis and Impaired Mitophagy. Toxicol Sci, 153, 198–211. 
Zhang, L. et al. (2016) Editor’s Highlight: Perfluorooctane Sulfonate-Choline 
Ion Pair Formation: A Potential Mechanism Modulating Hepatic Steatosis and 
Oxidative Stress in Mice. Toxicol. Sci., 153, 186–197. 
Zhang, Y. et al. (2013) Biomonitoring of Perfluoroalkyl Acids in Human Urine 
and Estimates of Biological Half-Life. Environ. Sci. Technol., 47, 10619–
10627. 
Zhou, J. et al. (2006) A Novel Pregnane X Receptor-mediated and Sterol 
Regulatory Element-binding Protein-independent Lipogenic Pathway. J Biol 




Figure 1. Dietary fat determines PFOS and PFNA modulation of hepatic 
lipids. 1A.) Lipid moieties were quantified from hepatic lipid extracts and 
normalized to liver weight, expressed as mg/g. Statistical significance was 
calculated using one-way ANOVA where *: significant from the LFD control, #: 
significant from the HFD control, $: significance between PFOS and PFNA 
within each diet and &: significance between diet within each compound. 1C.) 
Representative H&E stained liver sections. Scores were converted to ranks 





Figure 2. PFOS and PFNA exhibit diet and structure dependent effects on 
the hepatic transcriptome. Global transcriptomic analysis was conducted on 
n=3 samples from each group using a Mouse ST 2.0 transcriptomic array from 
Affymetrix detecting 34,472 total genes. The data was analyzed using 
Transcriptome Analysis Console (TAC) software by Affymetrix. The cutoff 
values were set at 1.5-fold change or greater and a p-value < 0.05. The raw 
data is available on the GEO database accession # GSE138602. 2A. and 2C.) 
Each Ven Diagram shows the overlap between PFOS and PFNA modulated 
genes relative to dietary controls. The genes on the left side are the top 10 
induced genes, while the genes on the right side are the top 10 suppressed 
genes. 2B. and 2D.) Scatter plots were generated using TAC software and show 
direct differential expression based on the log2 of the average signal for each 
PFOS and PFNA treatment group.   
 
Figure 3. PFOS and PFNA exhibit diet and structure dependent effects on 
the hepatic transcriptome. The raw data is available on the GEO database 
accession # GSE138602. 3A. and 3C.) Each Ven Diagram shows the overlap 
between LFD + PFAS and HFD + PFAS modulated genes relative to dietary 
controls. The genes on the left side are the top 10 induced genes, while the 
genes on the right side are the top 10 suppressed genes. 3B. and 3D.) Scatter 




expression based on the log2 of the average signal for each diet + PFAS 
treatment group.    
 
Figure 4. PFOS and PFNA significantly modulate many transcriptional 
drivers related to lipid homeostasis within the liver. Upstream analysis was 
used to predict transcriptional drivers. Orange signifies activation and blue 
signifies predicted upstream regulator inhibition. Activation or inhibited or a 
transcriptional regulator was predicted based on the expression state of the 
downstream targets and a z-score for activation or inhibition was assigned using 
Ingenuity Pathway Analysis software by Qiagen.  
 
Figure 5. PFOS and PFNA significantly modulate many pathways related 
to lipid homeostasis within the liver. The color gradient represents IPA 
generated pathway inhibition or activation scores, called z-scores. Orange 
signifies activation and blue signifies predicted pathway inhibition. Activation or 
inhibition of functional pathways was predicted based on the direction of 
modulation and the number of genes involved in the pathway. 
 
Figure 6. PFOS and PFNA significantly modulate many gene expression 
related to lipid accumulation, metabolism, and oxidative stress on the 
targeted level. A targeted Quantigene panel measuring 36 genes was 




normalized to beta actin as a housekeeper. The value in each cell represents 
the average fold change relative to the LFD control for n=5 samples.  
 
Figure 7. Diet interactions shift the hepatic proteome and PFNA is a potent 
modulator. Global protein analysis was conducted using SWATH-MS DIA 
proteomics. The raw and processed data is accessible via ProteomeXchange 
with identifier PXD015977. The data was analyzed using MaxQuant and 
Persues software. The data was filtered for contaminants and the cutoff for 
significance was set as p<0.05. The principal component analysis was created 
using Perseus software and represents the treatment effect on global hepatic 
protein expression. 
 
Figure 8. Structure specific interactions shift the hepatic proteomic 
signature of PFNA and PFOS. Each Ven Diagram depicts the overlap between 
the significantly modulated proteins from each treatment group. Significance 
was calculated on the SWATH-MS acquired data using MaxQuant software. 
 
Figure 9.  PFOS and PFNA significantly modulate protein expression 
related to lipid accumulation, metabolism, and oxidative stress on the 
targeted level. SWATH DIA-acquisition files were imported into Skyline 
(MacCoss Lab Software) for targeted protein expression analysis. Each protein 
expression values represents the average expression of two library matched 




controls. Average expression intensity (n=5) was converted to fold change and 
presented in each cell. Orange indicates activation, whereas blue indicates 
inhibition relative to control.  
 
Figure 10. Mechanistic drivers of PFAS-diet interactions. Significance was 
calculated using one-way ANOVA followed by Fisher’s LSD test. *, p<0.05, 
significance from the LFD controls. #, p<0.05, significance from the HFD 
controls. $, p<0.05, significance between PFOS and PFNA within the same diet 
(i.e. L/HPFOS vs L/HPFNA). &, p<0.05, significance between diet treatment 
within the same compound (i.e. LPFAS vs HPFAS). 10A.) Expression is 
presented as the log2 of the average signal ± SEM. The values were generated 
via transcriptomic array on n=3 individual samples per treatment group. 10B.) 
Male C57BL6 mice were fed with either a low fat diet or a moderately high fat 
diet with or without PFOS or PFNA (0.0003% w/w in feed) for 12 weeks. After 
necropsy, PFOS and PFNA were extracted from liver and quantified using LC-
MS/MS. All control groups exhibited PFOS and PFNA concentrations below the 
lower limit of quantification (LLOQ). Likewise, no quantifiable cross-
contamination between PFOS and PFNA treated groups was found. All values 
are means ± SEM; n = 7-8. 10C.) HPFNA and HPFOS enhanced activity of 
Ppar𝛼𝛼 relative to dietary controls and LPFAS groups. Ppar𝛼𝛼 activation causes 
a reduction in Oatp expression, a known uptake transporter for PFAS. 




(FFAs) from diet creates increased competition for fatty acid uptake 






Table 1.  Body and Tissue Weights 
 
Unit LFD LPFOS LPFNA HFD HPFOS HPFNA 





WAT Weight g 0.9±0.2# 1.3±0.1*#$& 0.5±0.1*#$& 2.2±0.1* 2.3±0.1*$& 1.6±0.1*#$& 
Liver Weight g 1.1±0.1 1.3±0.1$ 2.8±0.3*#$ 1.5±0.1 1.7±0.0$ 2.6±0.2*#$ 
Liver:BW % 4.4±0.7 4.3±0.1$& 10.2±1.0*#$& 3.4±0.3 4.1±0.1$& 7.4±0.5*#$& 
WAT:BW % 2.9±0.4# 4.3±0.2*#$& 1.7±0.3*#$& 5.3±0.3* 5.7±0.3*$& 4.6±0.2*$& 








Male C57BL6 mice were fed with either a low fat diet or a moderately high fat 
diet with or without PFOS or PFNA (0.0003% w/w in feed) for 12 weeks. After 
euthanization, gross body and organ weights were recorded and analyzed. *, 
p<0.05, significant in comparison to the LFD control. #, p<0.05, significant in 
comparison to the HFD control. $, p<0.05, significance between PFOS and 
PFNA within the same diet (i.e. L/HPFOS vs L/HPFNA). &, p<0.05, significance 




Table 2. Lipid Accumulation Scores 
 
The lipid accumulation score assigned out of total mice per group. Assigned 
scores ranged from 0 to 4, with 0 being the least and 4 the most severe. 
Statistical analysis was performed using Kruskal–Wallis test to derive ranks 
followed by Dunn's multiple comparison test for multiple comparisons using 
GraphPad Prism software v8.2.0 (La Jolla, CA). *, p<0.05, significant in 
comparison to the LFD control. #, p<0.05, significant in comparison to the HFD 
control. $, p<0.05, significance between PFOS and PFNA within the same diet 
(i.e. L/HPFOS vs L/HPFNA). &, p<0.05, significance between diet treatment 
within the same compound (i.e. LPFAS vs HPFAS).  
Treatment LFD LPFOS LPFNA HFD HPFOS HPFNA 
0 3/8 2/8 0/8 0/8 0/7 0/8 
1 5/8 3/8 4/8 0/8 1/7 2/8 
2 0/8 3/8 4/8 2/8 3/7 5/8 
3 0/8 0/8 0/8 5/8 3/7 1/8 
4 0/8 0/8 0/8 1/8 0/7 0/8 




Table 3. Top Global Hepatic Genes 
 
 
Transcriptomic array fold change and p-values were derived from the 
Transcriptome Analysis Console (TAC). The top genes were identified through 
the use of IPA (QIAGEN Inc.). The top 5 differentially expressed genes are 
summarized for each PFAS-diet comparison. Cyp2b10 was the top modulated 




















Cyp2b10 59.14 0.000021 Cyp2b10 26.99 0.005249 
Cyp2c55 15.86 0.000059 Mogat1 7.06 0.037019 
Cyp2c53 9.83 0.003011 Serpinb1a 7.02 0.001564 
Gstm3 8.79 0.00236 Gstm3 6.95 0.003246 
Cyp2b13 6.94 0.039922 Slc271 6.45 0.015992 
H vs HPFOS H vs HPFNA 
Cyp2b10 33.48 0.000018 Cidea 88.09 0.009264 
Gstm3 6.76 0.009034 Sptlc3 42.16 0.000055 
Cyp2c55 6.23 0.000548 Fabp3-ps3 38.98 0.000156 
Cyp4a12b 4.59 0.000737 Gm15441 22.9 0.000037 





Table 4. Effects of Upstream Transcriptional Regulators on NAFLD Onset.  
 
 Ppara Zbtb20 Pxr Car Ahr Nrf2 
HFD/LFD -- ++ ++ +++ ++ ++ 
LPFOS/LFD   +++ ++ -  
LPFNA/LFD + ++ + + -- +++ 
HPFOS/HFD + + ++ + --  
HPFNA/HFD +++ -- ++ - --- + 














et al., 2010, 
2) 
 
Treatment activation or inhibition of upstream regulators based on IPA derived 
z-scores using the upstream analysis feature. The number of pluses or minuses 
denotes the intensity of activation or inhibition. A blank well indicates no 
predicted effect. The impact of pathway activation on the onset or progression 












GENE NAME FUNCTION 
Acaca Acetyl-CoA Carboxylase Alpha enzyme that catalyzes the rate-limiting step in fatty acid synthesis 
Acot2 Acyl-CoA Thioesterase 2 regulation of lipid metabolism/intracellular levels of free fatty acids 
Cd36 Cluster Determinant 36 involved in long chain fatty acid uptake 
Cpt1a Carnitine Palmitoyltransferase 1A catalyzes mitochondrial uptake of fatty acids for beta-oxidation 
Cpt1b Carnitine Palmitoyltransferase 1B rate-controlling enzyme of fatty acid beta-oxidation 
Ehhadh Enoyl-CoA Hydratase And 3-Hydroxyacyl CoA 
Dehydrogenase 
enzyme in fatty acid beta-oxidation pathway 
Slc271a Solute Carrier Family 27 Member 1A long-chain fatty acid (LCFA) uptake into the cell 
Cidea Cell Death Inducing DFFA Like Effector A binds to lipid droplets and regulates their enlargement 
Fabp1 Fatty Acid-Binding Protein 1 role in fatty acid uptake, transport, and metabolism 
Cyp4a14 Cytochrome P450 4A14 oxidation of medium chain fatty acids 
Ppar-𝜸𝜸 Peroxisome Proliferator-Activated Receptor 
Gamma 
nuclear receptor that activates the peroxisomal beta-oxidation pathway 
of fatty acids 
Csf2r𝜶𝜶 Colony Stimulating Factor 2 Receptor Alpha cytokine which controls the production, differentiation, and function of 
granulocytes and macrophages 
Ccl2 C-C Motif Chemokine Ligand 2 chemotactic factor that attracts monocytes and basophils 
Tnf-𝜶𝜶 Tumor Necrosis Factor Alpha cytokine involved in systemic inflammation 
Nrf2 Nuclear Factor Erythroid 2–Related Factor 2 transcription activator that up-regulates genes in response to oxidative 
stress 
Scd1 Stearoyl-CoA Desaturase involved in fatty acid biosynthesis 
Fas Fatty Acid Synthase  catalyzes fatty acid synthesis 
Fabp4 Fatty Acid-Binding Protein 4 role in fatty acid uptake, transport, and metabolism 
Lpl Lipoprotein lipase functions as a triglyceride hydrolase and ligand for lipoprotein uptake 
Hmgcs1 3-Hydroxy-3-Methylglutaryl-CoA Synthase 1 catalyzes the formation of HMG-CoA 
Gstm3 GSTM3 glutathione S-transferase mu 3 mediates uptake and detoxification of both endogenous compounds and 
xenobiotics 
Nqo-1 NAD(P)H Quinone Dehydrogenase 1 involved in detoxification pathways 
Gclc Glutamate-Cysteine Ligase Catalytic Subunit the first rate-limiting enzyme of glutathione synthesis 
Sod1 Superoxide Dismutase 1 eliminates radicals which are toxic to biological systems 
Srebf1 Sterol Regulatory Element Binding Transcription 
Factor 1 
transcriptional activator for lipid homeostasis, regulates fatty acid and 
cholesterol synthesis 
Ppar-𝜶𝜶 Peroxisome Proliferator-Activated Receptor Alpha Transcription factor that regulates the beta-oxidation pathway of fatty 
acids 
 
Supplemental Table 1.Targeted hepatic genes and function. Genes 
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Supplemental Figure 1. Daily food consumption. Food consumption is 
expressed as average consumption per mouse per day over time. Each point 
represents average food consumed ± SEM. No significant difference in food 
















Supplemental Figure 2. Cd36 protein level expression. Representative 
western blot visually showing the relative Cd36 protein expression between 
treatment groups. An equal amount of protein input was loaded into each well. 
Relative diet and compound effects were confirmed using n=5 on subsequent 
blots normalized to beta actin. Primary Cd36 antibody was diluted 1:1000. The 
transferred membrane was incubated in primary antibody overnight at 4°C. Anti-
mouse Licor secondary antibody was used to produce the signal and the image 
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Non-alcoholic fatty liver disease (NAFLD) is most prevalent form of liver 
disease, affecting over 30% of Americans. Perfluoroalkyl substances (PFAS) 
represent a family of environmental toxicants that have infiltrated the living 
world. This study explores diet-PFAS interactions and their potential role in the 
increasing global incidence and progression of NAFLD. Male C57BL/6 mice 
were fed with either a low-fat diet (11% kcal from fat) or a high fat (58% kcal 
from fat) high carbohydrate (42g/L) diet with or without perfluorooctanesulfonic 
acid (PFOS) or perfluorohexanesulfonic (PFHxS) in feed (0.0003% w/w) for 29 
weeks. Proteomic, lipidomic, and gene expression measurement techniques 
were utilized to explore low-dose outcomes and mechanistic pathways. With 
administration of a high fat high carbohydrate (HFHC) diet, PFOS and PFHxS 
augmented macrovesicular steatosis, indicative of fatty liver. There was a clear 
shift in the lipidome of the serum exhibiting changes in phosphatidylcholines, 
phosphatidylethanolamines, plasmogens, sphingomyelins, and triglycerides 
with PFAS exposure. Finally, chain length exerted significant influence on tissue 
partitioning and the resulting hepatic gene and protein signatures of PFHxS and 





 INTRODUCTION  
Perfluoroalkyl substances (PFASs) represent a family of man-made fluorinated 
chemicals widely used in manufacturing and consumer products since the 
1940s.  The legacy PFASs are highly resistant to degradation and are slow to 
excrete from the human body, with half-lives spanning several years. PFASs 
have become ubiquitous within human serum, detectable in over 98% of the 
general population (Calafat et al., 2007). Perfluorooctanesulfonic acid (PFOS) 
and perfluorohexanesulfonic (PFHxS) are two of the most prevalent PFAS 
members detected in humans. PFOS has an 8-carbon (C8) fully fluorinated 
backbone while PFHxS is a 6-carbon (C6) PFOS replacement compound. Both 
PFOS and PFHxS contain a sulfonic acid headgroup and exhibit long half-lives, 
5.4 and 8.5 years respectively (Olsen et al., 2007). PFAS manufacturing 
companies had phased PFOS out of production by 2015, however, PFHxS may 
still be manufactured today as a replacement. In 2016 the EPA updated the 
health advisory level for PFOS to 70ppt in drinking water, based on a NOAEL 
dose for developmental toxicity in rodents (0.1mg/kg/day). While there has been 
some state level regulation, currently no federal health advisory level for PFHxS 
has been released. PFAS exposure is associated with adverse health effects 
related to metabolic and immune function including impaired immune response 
to vaccination (Grandjean et al., 2012), elevated serum cholesterol (Nelson et 
al., 2010), and increased serum marker of liver injury (Salihovic et al., 2018).   
Non-alcoholic fatty liver disease (NAFLD) represents a spectrum disease that 




Americans. The first stage of NAFLD, non-alcoholic fatty liver (NAFL), is 
characterized by the presence of macrovesicular steatosis within hepatocytes. 
The second stage, non-alcoholic steatohepatitis (NASH) is diagnosed by the 
presence of hepatic steatosis with inflammation and hepatocyte damage. If the 
fibrosis associated with NASH becomes severe enough to impair liver function, 
the patient progresses to the final stage known as cirrhosis.  Until the patient 
loses significant liver function, NALFD is a silent disease that requires an 
invasive liver biopsy for definitive diagnosis (de Alwis et al., 2016). The largest 
risk factor for NAFLD is believed to be metabolic syndrome, a common health 
problem associated with diet-induced obesity. In fact, dietary and lifestyle 
changes is the number one recommended treatment option for NALFD patients. 
According to the American Liver Foundation, only 20% of patients with NALF 
will progress to the inflammatory stage of NASH. The risk factors that determine 
patient progression to NASH are not well understood. However, the combination 
of complex sugars and fats is known to be pro-inflammatory and has been used 
in diet-induced models of in NASH in rodents.  
It has been well established in the literature that PFAS can induce hepatic 
steatosis in animals when administered with a lean standard mouse chow (Wan 
et al., 2012; Kudo et al., 2006; Bagley et al., 2017; Curran et al., 2008). PFASs 
are known for their ability to activate and interact with fatty acid binding and 
sensing molecules in the body. This is believed to be attributable to their 
structural similarity to endogenous fatty acids. In order to better understand the 




PFASs interact with lipids and the liver in the presence of an inflammatory diet. 
Published to date, no study has examined the implications of chronic low-dose 
PFAS exposure on the diet-induced progression of fatty liver disease. Only a 
handful of papers have evaluated high fat diet-PFAS interactions and only two 
evaluated liver pathology (Huck et al., 2018; Cho et al., 2016; Rebholz et al., 
2016; Tan et al., 2013; Wang et al., 2011). Only one study to date examines the 
effect of chronic NOAEL level exposure to PFOS in the context of NAFLD (Huck 
et al., 2018). Huck et. al. evaluated the role of PFOS on the onset of NAFL but 
did not examine the progression of simple hepatic steatosis to NASH. The 
current study utilizes a model for diet-induced NASH exposure and a sub-
chronic exposure window of 29 weeks to evaluate the role of PFOS and PFHxS 
in NASH disease progression. Furthermore, this study is unique in that will 
explore the potential chain length effect between PFHxS (C6) and PFOS (C8) 
and uses serum lipidomics to evaluate potential serum biomarkers for PFAS 
exposure. Few studies have assessed the effect of PFAS on overall lipidomic 
changes, and even fewer assessed the additional effect of diet on PFAS 
modulation of the blood lipidome. The present study is the first to investigate the 
influence of PFAS-diet interactions on the serum lipidome and the relative 
partitioning of PFASs between the liver and the serum.  
 
MATERIALS AND METHODS  
Animals. The study was conducted at the University of Rhode Island in 




C57BL/6 were acquired from Jackson Labs (Bar Harbor, ME USA) at eight 
weeks old. The mice were acclimated for two prior to being weight paired and 
housed three per cage in a temperature-controlled room. A strict 12-hour 
dark/light cycle was maintained with access to food and water ad libitum. Body 
weights, water, and food consumption were monitored throughout the study. 
Following 29 weeks of diet and PFAS administration, mice were anesthetized 
using isoflurane and sacrificed by cardiac puncture. Gross liver weight was 
recorded prior to sectioning in 10% formalin for histology. The remaining tissues 
were snap frozen in liquid nitrogen for downstream analysis.   
 
PFOS and PFHxS in Feed. The study design was based on a published model 
of diet-induced NASH (Marin et al., 2016). The mice received either a 11% kcal, 
low fat diet (LFD) (D12328, Research Diets, New Brunswick), or a 58% kcal, 
high fat diet (HFD) (D12331, Research Diets, New Brunswick). The mice that 
received a high fat diet were also administered high carbohydrates both through 
the sucrose content of the high fat diet and through carbohydrates added to 
drinking water at 42g/L (55% fructose : 45% sucrose). The mice were assigned 
to either diet alone, as controls, or to diet containing 0.0003% PFOS or 0.0003% 
PFHxS. The PFOS and PFHxS chemical stocks were obtained from Sigma-
Aldrich (St. Louis, MO, USA). The resulting treatment groups are as follows: low 
fat diet (LFD), high fat high carbohydrate diet (HFHC), LFD + PFOS (LPFNA), 
HFHC + PFOS (HPFOS), LFD + PFHxS (LPFHxS), and HFHC + PFHxS (HPFHxS) 




~0.3mg/kg/day. In the current EPA health advisory document for PFOS, 0.3 
mg/kg/day is considered a NOAEL dose for PFOS induced developmental 
toxicity.  
 
Hepatic Lipid Isolation and Analysis. Liver lipids were isolated for enzymatic kit 
based lipid quantification using the Folch chloroform-methanol extraction 
method (Folch et al., 1957). Serum and liver triacylglycerides (TAG) and total 
cholesterol, were measured using enzymatic kits from Pointe Scientific (Ann 
Arbor, MI USA). At the time of necropsy, liver tissue sections taken from the 
largest lobe were fixed in 10% buffered formalin. The sections were paraffin 
embedded, cut, and stained with hematoxylin and eosin (H&E). Stains and 
scoring were conducted by Rutgers University Research Pathology Services 
(Piscataway, NJ).  Lipid accumulation scores were assigned by a board-certified 
pathologist, ranging from 0 to 5, with 0 being the least and 5 the most severe. 
 
Serum Lipid Isolation. Serum liver lipids were isolated for lipidomic analysis 
according to the Bligh and Dyer method (Bligh and Dyer, 1959). The lipidomics 
was performed at the University of Georgia (Athens, GA). Briefly, blood samples 
designated for lipidomics were suspended in 1.25 ml of methanol and 1.25 ml 
of chloroform. Tubes were vortexed for 30 s, allowed to sit for 10 min on ice, 
centrifuged (300 x g; 5 min), and the bottom chloroform layer was transferred to 
a new test tube. The extraction steps were repeated three times and the 




standards (Avanti Polar Lipids, Inc.) were spiked into each sample. SPLASH 
Lipidomix Mass Spec standards includes all major lipid classes at ratios similar 
to that found in human plasma. The collected chloroform layers were dried 
under nitrogen, reconstituted with 50 µl of methanol: chloroform (3:1 v/v), and 
stored at 80ºC until analysis. Lipid content was quantified by determining the 
level of inorganic phosphorus using the Bartlett Assay (Bartlett, 1959).  
 
Serum Lipidomic Analysis  
Lipid extracts (500 pmol/µl) were prepared for ESI-MS/MS by reconstitution in 
chloroform: methanol (2:1, v/v).  ESI-MS was performed on a 5 µl aliquot of each 
sample as previously described (Zhang et al., 2005) using a LCQ Deca ion-
mass spectrometer (LCQ Finnigan mass spectrometer (Thermo Fisher-Fenning 
Institute, CA) with nitrogen drying gas flow-rate of 81/min at 350 ºC and a 
nebulizer pressure of 30 psi. The scanning range was from 200 to 1000 m/z in 
positive and negative mode for 2.5 min. The mobile phase was acetonitrile; 
methanol; water (2:3:1) in 0.1% ammonium formate. Samples were run in 
triplicate (n = 3). Lipid extracts were also analyzed using a high resolution LC 
linear ion trap-Orbitrap Hybrid MS” (nanoHRLC-LTQ-Orbitrap MS) (Thermo 
Scientific, San Jose, CA). Individuals running samples were blinded to sample 
conditions. Mass spectra were acquired in the positive ion mode. Mass 
spectrometric parameters for lipid extracts were as follows: spray voltage: 
3.5/2.5 kV, sheath gas: 40/35 AU; auxiliary nitrogen pressure: 15 AU; sweep 




respectfully. Full scan, data-dependent MS/MS (top10-ddMS2), and data-
independent acquisition were collected at m/z 150–2000, corresponding to the 
mass range of most expected cellular lipids. Lipids were separated on a 
nanoC18 column (length, 130 mm; i.d, 100 µm; particle size, 5 µm; pore size, 
150 Å; max flow rate, 500 nL/min; packing material, Bruker Micron Magic 18). 
Mobile phase A was 0.1% formic acid/water; mobile phase B was 0.1% formic 
acid/acetonitrile. 10 μL of each sample was injected for analysis. A constant 
flow rate of 500 nL/min was applied to perform a gradient profiling with the 
following proportional change of solvent A (v/v): 0 to 1.5 min at 98% A, 1.5 to 
15.0 min from 98% to 75% A, 15.0 to 20.0 min from 75% to 40% A, 20.0 to 25.0 
min from 40% to 5% A, 25.0 to 28.0 min kept at 5% A, and 28.0 to 30.0 min from 
5% to 98% A. The LTQ-Orbitrap Elite MS was set in the positive full scan mode 
within range of 50 to 1500 m/z. Settings of the electrospray ionization were: 
heater temperature of 300°C, sheath gas of 35 arbitrary unit, auxiliary gas of 10 
arbitrary unit, capillary temperature of 350°C, and source voltage of +3.0 kV. 
MS/MS fragmentation was induced using a collision-induced dissociation scan 
with a Fourier transform resolving power of 120,000 (transient = 192 ms; scan 
repetition rate = 4 Hz) at 400 m/z over 50–1500 m/z. Solvent extraction blanks 
and samples were jointly analyzed over the course of a batch (10–15 samples). 
 
Lipidomic Data Processing 
Full scan raw data files were acquired from Xcalibur™ (Thermo Fisher 




MSConvert. Data processing and peak area integration were performed using 
MZmine (Pluskal et al., 2010) and XCMS (Tautenhahn et al., 2012),resulting in 
a feature intensity table. Feature tables and MS/MS data were placed into a 
directory for each substrate analyzed. Each folder contained each sample type, 
feature tables end in “pos.csv” for positive mode. LipidMatch (Koelmel et al., 
2017) was used to identify features. Peak heights were normalized to a mixture 
of deuterium labeled internal standards for each sample (SPLASH® 
LIPIDOMIX® Mass Spec standard. Multivariate principal component analysis 
(PCA) was performed using MetaboAnalyst 4.0 (http://www.metaboanalyst.ca/).  
Automatic peak detection and spectrum deconvolution was performed using a 
peak width set to 0.5.  Analysis parameters consisted of interquartile range 
filtering and sum normalization with no removal of outliers from the dataset.  
Features were selected based on a one-way ANOVA analysis and were further 
identified using HPLC-MS/MS analysis. Significance for ANOVA plot analysis 
was determined based on a fold-change threshold of 2.00, q ≤ 0.05 and p ≤ 
0.05. Following identification, internal standards were used to normalize each 
parent lipid level, and the change in the relative abundance of the lipid species 
as compared to its control was determined. 
 
Quantifying Serum and Liver PFAS Content. LC-MS/MS was used to quantify 
hepatic and serum PFAS concentrations and to further explore the effect of diet 
on internal distribution of PFASs to the liver. PFASs were isolated from liver 




Roughly, 100mg of tissue was homogenized in water spiked PFOS C4 and 
PFHxS C3 internal standard. A fraction of the homogenate was digested 
overnight in 10% 1N KOH. 100μL of digested sample was mixed with 100μL 1N 
formic acid, 500μL 2N HCL, 500μL saturated ammonium sulfate, and 5mL LC-
MS grade MTBE. For serum PFAS extraction, 20μL of serum was mixed with 
200μL of 0.5 M tetrabutylammonium bisulfate, 400μL, 0.25 M sodium 
carbonate, internal standard spike, and 3mL of MTBE. For both liver and serum, 
the organic layer was transferred to a fresh tube and evaporated to dryness. 
The sample was re-suspended in acetonitrile: water and filtered through a 
0.2μm syringe filter prior to injection. The LC-MS/MS analysis was conducted 
on a QTRAP® 4500 LC-MS/MS System in negative mode using a Waters 
XBridge C18 (100mm x 4.6mm, 5μm) column.  
 
RNA Preparation and Expression Measurement. Trizol method was used to 
isolated hepatic RNA, quantified by a ThermoFisher Nanodrop 1000 and diluted 
with DEPC water to equal concentrations. Gene expression was measured 
using a custom QuantiGene Luminex xMAP gene expression panel (Thermo 
Fisher, Waltham, MA USA). The assay was conducted on a Bio-plex 200 
instrument (Biorad, Hercules, CA USA) according to the manufacturer’s 
protocol. The full list of hepatic genes measured, names, and functions can be 
found in Supplemental Table 1.  
 
Peptide Preparation and Proteomic Analysis. Hepatic protein samples (500 µg) 




for 30 min in a shaking water bath (100 rpm). After denaturation, samples were 
alkylated in the dark with 25 µL IAA (200 mM) for 30 min at room temperature. 
Samples were subsequently concentrated using the cold water, methanol and 
chloroform (1:2:1) precipitation method (centrifugation at 12000 rpm, 5min at 
10°C). Protein pellet was washed with ice-cold methanol and then suspended 
in 200 µL of 50 mM ammonium bicarbonate (pH 8) containing 3% w/v sodium 
deoxycholate (DOC). One hundred of the reduced and alkylated protein sample 
was taken for digestion (500 µg protein was taken due to poor pellet formation. 
However, only 250 µg protein was digested with trypsin). Further, TPCK-treated 
trypsin (10 µg) was added to samples at a ratio of 1:25 (trypsin:protein) and 
samples were transferred into digestion tubes (PCT MicroTubes, Pressure 
Biosciences Inc.,Easton, MA). The barocycler was run at 35°C, for 90 cycles 
with 60 sec per pressure-cycled (50 sec high pressure, 10 sec ambient 
pressure, 25 kpsi). Further, 100 µL of digested peptides sample was mixed with 
10 µL of ACN (1:1, v/v containing 5% formic acid) to precipitate detergent. 
Samples were spun to remove the pellet and 100 µL supernatant was collected 
(12000 rpm for 5 min at 10°C). Subsequently, twenty microliters of the resulting 
peptide solution were injected on the analytical column and were analyzed using 
LC-MS/MS. The SWATH-MS proteomics was conducted on an Acquity UHPLC 
HClass system (Waters Corp., Milford, MA, USA) coupled to a SCIEX 5600 
TripleTOF mass spectrometer (SCIEX, Concord, Canada). The separation of 
the peptides was achieved using a runtime of 60 min at 100 μL/min and a linear 




published (Jamwal et al., 2017). Opensource softwares, MaxQuant (Tyanova, 
Temu, and Cox, 2016) and Perseus (Tyanova, Temu, Sinitcyn, et al., 2016) 
were used to assess global changes and total proteins detected. Skyline 
(MacLean et al., 2010) was utilized to determine relative expression for targeted 
proteins. For each targeted protein, the peak area of two peptides, represented 
by at least three daughter ions and library matched to the parent protein, were 
averaged. This peak area was normalized to BSA digestion control as well as 
measured sample peptide concentration.  
 
Statistical Analysis. Table values are shown as the average ± standard error 
(SEM). Significance was derived using one-way analysis of variance (ANOVA) 
followed by Fisher’s LSD test for multiple comparisons where p < 0.05 was 
denoted as statistically significant. Statistical tests were performed using 




Low dose PFHxS augments white adipose weight within a high fat diet. 
HFHC feeding caused a 27.4% increase in body weight and 55.7% in liver 
weight compared to LFD controls (Table 1). Surprisingly, the LFD significantly 
augmented white adipose tissue (WAT): body weight (BW) ratio, by 29.1% 
compared to the HFHC treatment controls. Within the LFD, PFOS increased 
liver weight by 53.8% and liver:body weight by 61.8% more than its 6 carbon 




HFHC group by 43.7% and 19.4% in comparison to HFHC control and HPFOS 
respectively. This is further supported by an observed 37.7% increase in 
WAT:BW with HPFHxS administration compared to HFHC control. This finding 
is in opposition to the decrease in WAT typically observed in rodent studies 
using higher doses of PFOS.  
 
Diet composition exerts a significant impact on hepatic lipid content and 
pathology.  
An excess influx of dietary lipids and carbohydrates can trigger hepatic lipid 
accumulation and the onset of steatosis. Serum and hepatic lipids were 
assessed (Figure 1). Food was provided to the mice ad libitum, and 
consumption was monitored. Supplemental Figure 1 depicts the average daily 
food consumption per mouse over the first 60 days. The LFD mice consumed 
significantly more food than the HFHC treatment groups. Furthermore, the 
PFAS mice treated mice consumed more food on average than the LFD controls 
with LPFOS mice consuming more than LPFHxS. Food consumption among 
the HFHC treatment groups was similar.  To explore PFAS effects on hepatic 
lipids, hepatic and serum total cholesterol and triglycerides were measured 
(Figure 1A). Both PFOS and PFHxS caused a significant reduction in total 
serum cholesterol compared to the HFHC controls. In addition, PFOS caused a 
significant reduction in total serum triglycerides compared to both the HFHC and 




To visualize liver pathology, liver sections were stained by H&E and scored by 
a board-certified pathologist for lipid accumulation, inflammation, and biliary 
hyperplasia. Figure 1B depicts a representative image for each treatment group. 
The black arrows highlight hepatic lipid droplets indicative of steatosis, as well 
as PFAS induced alterations in lipid droplet structure and size.  All treatment 
groups, including the LFD controls, exhibited macrovesicular hepatic steatosis 
consistent with fatty liver disease. The prevalence of fatty liver within the LFD 
controls was likely caused by the advanced age of the mice at the time of 
necropsy and the significant overconsumption within the LFD groups. 
Surprisingly, 50% of both the HFHC and the LFD fed mice scored ≥3 for lipid 
accumulation (Table 2). Within the LFD, PFOS and PFHxS reduced this lipid 
accumulation with 33% and 0% scoring ≥3. However, PFAS exerted the 
opposite effect in the HFHC diet scoring 83% for HPFOS and 100% for 
HPFHxS. Visually, there is a clear change in the lipid droplet structure within the 
PFAS treated mice when compared to the controls. HPFOS, LPFOS, and 
HPFNA increased the relative abundance of microvesicular lipid droplets in 
comparison to controls. Inflammation is an important feature of the progression 
of NAFL to NASH. Interestingly, diet significantly modulated hepatic 
inflammation induced by PFAS, following a similar trend as lipid accumulation 
(Table 4). HPFOS and HPFHxS showed significantly increased inflammation 
when compared to LPFOS and LPFHxS respectively. Moreover, PFAS 
exposure significantly increased biliary hyperplasia within both diets (Table 5). 




severity of inflammation and lipid accumulation when compared to PFAS 
exposure within a LFD.  
 
Diet alters partitioning of PFOS and PFHxS between liver and serum.  
To examine if diet influences partitioning of PFOS and PFHxS between the 
serum and the liver, hepatic and serum PFOS and PFHxS were quantified by 
LC-MS/MS (Table 5). PFOS achieved significantly higher cumulative 
concentrations, 125.2 and 130.3μg/g, relative to PFHxS at 83.7 and 43.2μg/g 
for LFD + PFAS and HFHC + PFAS respectively. In addition, HPFHxS achieved 
significantly lower cumulative concentrations than LPFHxS. In the liver, LPFOS 
deposition was greater than PFHxS. In the serum, LPFHxS concentration was 
over 3 times higher than that of LPFOS. HPFHxS showed a slight elevation in 
serum content compared to HPFOS, despite significantly lower total 
accumulation. When taken together, these findings suggest that the chain 
length of PFOS and PFHxS plays a prominent role in relative distribution 
between the serum and liver. Furthermore, diet seems to pose a prominent 
influence on PFAS retention and excretion.  
 
Low dose PFOS and PFHxS exposure causes significant untargeted shifts 
in the global mouse serum lipidome. 
PFAS exposure causes significant dysregulation of the mouse blood lipidome. 
Multivariate, unsupervised principal component analysis (PCA) scores plots of 




in the presence of both LFD and HFHC showed distinct clustering. A supervised 
PLS-DA of the blood lipidome demonstrated separation between the blood 
lipidome of mice exposed to the LFD and the LFD in the presence of both 
PFASs (Supplemental Figure 3A). Moreover, similar results were observed for 
mice exposed to the HFD and those exposed to the HFD containing both PFASs 
(Supplemental Figure 4A). Cross validation values of these PLS-DA models 
confirmed discrimination between PFASs in the presence of both LFD and HFD, 
with  an accuracy value from 0.35 to 0.8 value of R2 Model quality, as evaluated 
using R2Y and Q2 values, which reflect the explained fraction of variance and 
model predictability (Supplemental Figure 3B, 3C and  4B, 4C). These data 
suggest that exposure of mice to both PFASs and diet induce differential 
lipidomic profiles within the blood lipidome.  
 
Low dose PFOS and PFHxS exposure causes significant targeted shifts in 
the mouse serum lipidome. 
Targeted lipidomics was performed to identify specific changes between the 
blood lipidome of mice exposed to the LFD and HFHC. Based on the diet-related 
comparisons, HPLC-ESI MS/MS was employed to identify the number of 
features altered between sample types. Blood from mice exposed to LFD and 
HFHC in the presence and absence of PFASs were analyzed using HPLC-ESI-
Orbitrap-MS/MS and the results were analyzed by a cloud plot analysis (Figure 
2). A total of 2,918 dysregulated ion features were identified, encompassing 28 




that experienced a significant fold-change. The data agree with the above 
mentioned ESI-MS analysis supporting the conclusion that PFAS exposure 
alters the effect of both LFD and HFHC on the blood lipidome.  
 Diet-related pairwise comparisons identified 146 dysregulated ion features 
between these two groups, as shown by cloud plot (Figure 2B). LC-ESI-MS/MS 
analysis of the blood lipidome from mice exposed to the LFD, in comparison to 
LPFOS, identified 1,121 dysregulated ion features between these two groups 
(Figure 2C). A similar analysis was used to compare changes in the lipidome of 
blood isolated from mice exposed to the LFD and those exposed to LPFHxS.  A 
total of 283 dysregulated ion features were identified between these two groups 
(Figure 2D).  
A total of 546 dysregulated ion features were identified in blood isolated from 
mice exposed to the HFHC in comparison to HPFOS (Figure 2E). A similar 
analysis was used to compare changes in the blood lipidome in mice exposed 
to HFHC versus HPFHxS. This analysis identified 841 dysregulated ion features 
dysregulated between the two groups (Figure 2F).  These data were used to 
identify the specific lipids altered in the blood of mice exposed to PFASs and to 
determine changes in the levels of these lipids. 
 
PFOS and PFHxS significantly modulate serum phospholipids, 
triacylglycerdies, and plasmogens in the presence of either a LFD or 




Targeted and internal standard validated analysis of the shifted serum lipid 
moieties was performed by LC-MS/MS. The HFHC diet significantly modulated 
the abundance of serum phosphatidylcholine (PC) moieties relative to the LFD 
(Figure 3). Phosphatidylcholine (PC) lipids were enriched in the blood of mice 
exposed to LFD + PFAS when compared to LFD controls (Figure 3A). Amongst 
the PC lipids, 14:0-22:2 PC was identified as a dominant species enriched in 
the blood of mice exposed to LPFOS and LPFHxS diets, as well as HFHC, 
relative to LFD controls (Figure 3B). There was significant attenuation of OxPC 
in the blood of mice exposed to the HPFHxS diet as compared to the HFHC 
alone (Figure 3C). Surprisingly, oxidized lysoPC (OxLPC) was significantly 
enriched in the blood of mice exposed to the LPFHxS diet, as compared to the 
LFD (Figure 3D).  However, there was a significant decrease with LPFOS 
compared to LFD. Figure 4 depicts further modulation of phospholipid moieties, 
phosphatidylethanolamine (PE), lysoPE (LPE), and their oxidized forms (OxPE 
and OxLPE). Within the LFD, levels of phosphatidylethanolamine (PE) were 
decreased in the blood of mice exposed to the PFHxS and PFOS (Figure 4A). 
Similar results were observed with HPFHxS and HPFOS exposure relative to 
HFHC control. Relative to the LFD, partial hydrolysis of PE was attenuated by 
LPFHxS, LPFOS, and HFHC (Figure 4B) as determined by decreased 
measurement of lysoPE (LPC).  
In addition to phospholipids, further modulation of the serum lipidome by PFAS 
and diet was observed. Monogalactosyldiacylglycerol (MGDG) levels were 




to the LFD (Figure 5A). Within the HFHC, there was a significant decrease in 
mice exposed to PFHxS. The levels of oxidized triacylglycerides (OxTG) were 
attenuated in the blood of mice exposed to the LPFHxS and LPFOS relative to 
the LFD (Figure 5B). Sphingomyelin (SM) was significantly decreased in the 
blood of mice exposed to HFHC as well as those exposed to LPFHxS and 
LPFOS diets, as compared to the LFD (Figure 6A). Surprisingly, plasmalogen 
levels were increased in the blood of mice exposed to the LPFOS and LPFHxS 
diets, as compared to LFD control (Figure 6B).  Plasmalogen levels were also 
increased in the HPFHxS group as compared to HFHC, yet were decreased in 
the blood of mice exposed to the HPFOS diet. 
Lipid pathway enrichment analysis (LIPEA) was conducted to identify the top 
pathways altered by PFAS and diet. The majority of lipids (50%)  altered in 
response to either HFHC or PFAS exposure correlated to glycerophospholipid 
metabolism (Supplemental Table 2). Other pathways identified included those 
mediating sphingolipids, ferroptosis, choline metabolism in cancer, retrograde 
endocannabinoid signaling and necroptosis. Overall, PFAS exposure caused 
notable shifts in the serum lipidome and diet further influenced PFAS modulated 
lipid moieties.   
 
PFOS and PFHxS modulate serum and hepatic lipids via modulation of 
hepatic pathways. 
 The expression of key genes and proteins involved in lipid metabolism, 




genes, names, and functions is further described in Supplemental Table 1. The 
expression data is summarized as fold change relative to either the LFD or 
HFHC controls in Figure 6. Overall, PFOS had a more potent effect on hepatic 
gene expression. Slc27a1 expression was induced by LPFOS by 2.0 and 
HPFOS 2.5-fold compared to 1.2 LPFHxS and 0.9-fold for HPFHxS. The 
combination and diet and PFAS chain length also exerted influence over gene 
expression. For example, Acaca was highly induced by both PFASs in the LFD 
3.3 and 3.6-fold, whereas induction was only 1.1 and 1.5 relative to the HFHC 
diet. Gstm3 was significantly repressed 0.2-fold by LPFHxS but not for HPFHxS. 
For LPFOS, there was no appreciable effect on Gstm3 expression, yet it was 
induced 3.6-fold by HPFOS relative to respective control. Protein level effects 
showed similar diet-PFAS specific changes on markers of oxidative stress. 
Gstm3 was slightly repressed only by LPFHxS and induced by 3.1-fold by 
HPFOS.  On the protein level, increased potency of PFOS on is apparent 
(Figure 7). Notably, HFHC groups caused stronger induction of several 
oxidative stress related proteins including, Ces1, Gstm2, Gstm3, and Gstm7.  
The diet specific PFAS modulation of hepatic lipids may be explained by altered 
expression of lipid uptake transporters, lipid droplet enlargement protein, and 
changes in fatty acid synthesis (Figure 8A). Diet specific induction of fatty acid 
uptake transporters, Fabp4 and Cd36, was observed. Increased fatty acid 
uptake can promote liver lipid accumulation. Furthermore, we observed 
enhanced induction of the fatty acid synthesis gene, Fas and an important 




groups specifically. All four genes could have attributed to the increased the 
hepatic lipid uptake observed only in the HFHC + PFAS treated groups. 
Furthermore, alterations of the serum lipidome may be explained by PFAS and 
diet induced changes in the hepatic expression of oxidative stress related and 
oxidizing genes (Figure 8B). Nrf2 is a transcription factor that is activated in the 
presence of oxidative stress and drives the transcription of antioxidant response 
genes. Nrf2 and its target genes Gstm3, Nqo1, and Gclc were upregulated by 
the HFHC diet. This enhanced expression could indicate increased oxidation 
and oxidative stress in the liver. This elevated oxidative stress in the HFD + 
PFAS groups correlates back to the increased presence of oxidized lipid 
moieties observed in the serum lipidome.  
 
DISCUSSION 
A major limitation of the present study is the overconsumption observed in the 
LFD diet groups. It is likely that this overconsumption was the driver of the 
induced fatty liver observed in the LFD controls. Furthermore, the mice were at 
an advanced age, 39 weeks, at the time of necropsy further contributing to an 
elevated risk of metabolic dysfunction. Despite significantly higher consumption 
in the LPFOS and LPFHxS groups relative to the dietary control, LPFOS and 
LPFHxS caused a counterintuitive protective effect by attenuating the severity 
of steatosis and inflammation observed in the control. This low fat diet effect on 
liver pathology is similar to the phenomenon observed by Huck et. al, who found 




within a high fat diet.  In contrast, in the present study the HFHC + PFAS groups 
actually worsened hepatic lipid accumulation. Perhaps the protective 
mechanism of PFASs against hepatic steatosis within a HFD can be 
overwhelmed or the addition of high carbohydrates to the drinking water altered 
the interaction between PFASs, diet, and the liver. Given the current and 
previous findings, it is clear that diet plays a critical role in modulating PFAS 
induced NAFLD.  
Even taking diet consumption discrepancies into account, it is clear that diet and 
structure influenced the overall partitioning of PFASs as well as the retention of 
PFHxS. There is very little data available on the relative partitioning of PFASs 
between blood and liver in the presence of a HFD. One developmental study 
suggests that perinatal exposure followed by HFD consumption later in life 
increases hepatic retention of PFOS (Wan et al., 2014). In the present study, 
the data suggests that the HFD caused a reduction in hepatic PFAS 
accumulation accompanied by increased serum accumulation. Interestingly, the 
addition of a HFD reduced the total PFAS concentration suggesting that diet 
may modulate the rate of PFAS excretion. This diet effect on excretion could 
confound associations between PFAS concentration and NAFLD.  
Although a large number of epidemiology studies have examined the potential 
for PFASs to induce hepatic steatosis in correlation with other adverse effects, 
most of the studies do not evaluate the effect of diet in combination with PFAS 
on both the onset and progression of non-alcoholic fatty liver disease (NAFLD).  




cholesterol, LDL, HDL and others.  In contrast, few if any, have studied the 
ability of PFAS to alter the blood lipidome and correlated these changes to 
hepatic steatosis, even fewer have examined the effect of diet on either PFAS-
induced hepatic steatosis and changes in the blood lipidome.   The present 
study represents a first step toward identifying any such correlation. Data from 
both untargeted and targeted analysis of the mouse blood lipidome 
demonstrated diet-dependent shifts in the types and levels of lipids modulated 
by PFHxS and PFOS exposure. This analysis demonstrated that changes in the 
lipidome that were dependent on both diet and the presence of PFASs. 
Subsequent targeted analysis validated these data and identified the specific 
types of lipids altered.  These findings are consistent with the previous literature 
demonstrating that circulating PC levels were significantly augmented in (non-
alcoholic fatty liver (NAFL)) and non-alcoholic steatohepatitis (NASH) patients, 
as compared to healthy controls (Tiwari-Heckler et al., 2018) Contrary to PC, 
the level of PE, as well as lysophosphatidylcholine (LPC) and 
lysophosphatidylethanolamine (LPE) decreased. This trend was also seen in 
NAFL and NASH patients in comparison to controls.  
Oxidized lipids such as those derived from PC, LPC and TAG have not been 
previously associated with PFAS exposure. It is known that oxidized lipids are 
not simply by-products formed during lipid peroxidation reactions, but are key 
mediators in inflammation (Fu and Birukov, 2009) infection (Matt et al., 2015), 
and immune response (Cruz et al., 2008). Furthermore, oxidized lipids are 




Our findings are consistent with previous studies that demonstrate an increase 
in plasmalogen levels in steatotic and cirrhotic livers compared to normal livers 
(Barr et al., 2012).  Elevated plasmalogens are suggested to indicate increased 
activity of protective mechanisms against oxidative stress. Furthermore, 
plasmalogens are enriched in developing lipoproteins secreted by cultured rat 
hepatocytes where they may serve as endogenous plasma antioxidants (Vance, 
1990)  However, there are other reports that demonstrate that serum 
plasmalogen levels are decreased in patients with NASH and NAFLD as 
compared to controls (Puri et al., 2009). A decrease in plasmalogen levels could 
be associated with a more severe in NASH patients as opposed to steatosis 
patients. 
While this study represents the most comprehensive analysis of the effect of 
diet and PFAS exposure on the blood lipidome, it is limited as the actual 
concentrations for lipid species were not provided. This was in part intentional, 
and these data are meant to inspire further studies focusing on the roles of the 
specific lipids identified as altered in serum.  Furthermore, it is important to point 
out that many of these lipids are rather novel and do not have a suitable internal 
standard at this time to allow for absolute quantification.  
 
CONCLUSIONS 
This study demonstrated that exposure of PFAS in diet alters the effect of LFD 




the hypothesis that the effect of PFAS on lipids in vivo is diet-dependent. In the 
presence of a high fat high carbohydrate diet, PFOS and PFHxS worsened 
hepatic steatosis via increased the expression of genes involved in fatty acid 
uptake, synthesis, and lipid droplet expansion. Our findings are consistent with 
previous literature reports that both diet and PFAS can augment lipid outcomes, 
and this study provides new evidence that PFOS and PFHxS augment oxidative 
stress in the liver and increase oxidized lipid species in the sera. This study 
represents the first to characterize diet-PFAS impact on the blood lipidome.  The 
mechanisms by which PFASs may interfere with blood lipids in humans are not 
well understood.  These findings suggest a correlation between changes in the 
blood lipidome and PFAS induced hepatic steatosis providing a basis for 
identification of PFAS related lipid predictors. PFOS distributes to the liver more 
efficiently than its 6-carbon alternative PFHxS, yet PFHxS causes stronger 
modulation of liver pathology within the low and high fat diets. Overall, both diet 
and PFAS chain length exerted notable influence over lipid outcomes, PFAS 
partitioning, and PFAS excretion.    
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FIGURE LEGENDS  
Figure 1. Diet composition determines PFOS and PFHxS effects on 
hepatic lipids. Statistical significance was calculated using one-way ANOVA 
where *: significant from the LFD control, #: significant from the HFHC control, 
$: significance between PFOS and PFHxS within each diet and &: significance 
between diet within each compound. A) Lipid moieties were quantified from 
hepatic lipid extracts and serum and normalized to liver weight, expressed as 
mg/g or blood volume expressed as mg/dL. B) Representative H&E stained liver 
sections. Black arrows highlight examples of macrovesicular and microvesicular 






Figure 2. Diet and PFAS cause significant shifts in the global serum 
lipidome. Differential cloud plot demonstrating dysregulated lipid features in the 
blood of male mice (p < 0.05 threshold, fold change >= 1.5 threshold). Up-
regulated features (features that have a positive fold change) are graphed 
above the x-axis and are shown in green, while down-regulated features 
(features that have a negative fold change) are shown in red and are graphed 
below the x-axis. Only those features whose levels varied significantly (p < 0.05) 
are projected. Rows represents a metabolite feature and each column 
represents a sample. Data are indicative of 6 samples per group. A) 
Dysregulated lipid features between LFD and LFD with PFAS and HFHC and 
HFHC with PFAS. B) Differential expression of lipid  features between LFD and 
HFHC. C) Dysregulated lipid features between LFD and LPFOS. D) 
Dysregulated lipid features between LFD and LPFHxS. E) Dysregulated lipid 
features between HFHC and HPFOS. F) Dysregulated lipid features between 
HFHC and HPFHxS. 
 
Figure 3. Effect of PFOS and PFHxS on phosphatidylcholine (PC) levels 
within a LFD or HFHC diet. Lipidomic analysis was outsourced and performed 
using mass spectroscopy equipment at the University of Georgia. *** denotes 
p<.001; ** denotes p<.01 and * denotes p<.05. Scatter plots showing levels of 
phosphatidylcholines lipid moieties in sera between control and PFAS treated 





Figure 4. Effect of PFOS and PFHxS on phosphatidylethanolamine (PE) 
levels within a LFD or HFHC diet. Data are indicative of 6 samples per group 
and are expressed as the mean ± the SEM (*p < 0.05 **p < 0.01*** p < 0.001) 
Normalized peak areas between all cells are shown for A) PC,  B) 14.0/22.0 
PC, C) OxPC, and D) OxLPC. Each symbol represents an individual lipid feature 
as identified by LC-MS/MS. 
 
Figure 5. Effect of PFOS and PFHxS on triacylglycerol levels in the blood 
of male C57BL/6 mice exposed to a LFD or HFHC diet. Data are indicative 
of 6 samples per group and are expressed as the mean ± the SEM (*p < 0.05 
**p < 0.01*** p < 0.001). Each symbol represents an individual lipid feature as 
identified by LC-MS/MS. Normalized peak areas between all cells are shown for 
A) monogalactosyldiacylglycerol (MGDG) and B) oxidized triacylglycerol 
(OxTG). Each symbol represents an individual lipid feature as identified by LC-
MS/MS. Data are compared based on normalized peak areas. 
 
Figure 6. Effect of PFOS and PFHxS on serum sphingomyelin and 
plasmogen levels within a LFD or HFHC diet. Data are indicative of 6 
samples per group and are expressed as the mean ± SEM (*p < 0.05 
**p < 0.01*** p < 0.001). Each symbol represents an individual lipid feature as 





Figure 7. PFAS-diet interaction alters hepatic gene expression to 
modulate lipids and pathology. A targeted Quantigene panel measuring 36 
genes was conducted on a Bioplex 2.0 system. Fluorescence intensity values 
were normalized to beta actin as a housekeeper. The value in each cell 
represents the average fold change relative to the LFD control for n=5 samples.  
 
Figure 8. PFAS-diet interaction alters hepatic protein expression to 
modulate lipids and pathology. Global protein analysis was conducted using 
SWATH-MS DIA proteomics on n=5 samples per treatment group. The data 
was analyzed using MaxQuant and Persues software. The data was filtered for 
contaminants and the cutoff for significance was set as p<0.05.  Targeted 
relative protein expression was derived Skyline. Each value is the average 
expression of two peptides for each parent protein, normalized to spike BSA 
control and measured protein input. The value is each cell represents the fold-
change value relative to the respective control diet.  
 
Figure 9. PFOS and PFHxS modulate hepatic lipid accumulation and 
oxidative stress. Targeted graphs of gene expression data showing average 
fold change ± SEM. Statistical significance was calculated using one-way 
ANOVA where *: significant from the LFD control, #: significant from the HFHC 
control, $: significance between PFOS and PFHxS within each diet and &: 




effects on genes related to lipid accumulation. B)  Highlights diet-PFAS effects 

















Table 1.  Body and Tissue Weights 
 
Male C57BL6 mice were fed with either a low fat diet (LFD) or a high fat high 
carbohydrate (HFHC) diet with or without PFOS or PFHxS (0.0003% w/w in 
feed) for 29 weeks. After euthanization, gross body and organ weights were 
recorded and analyzed. *, p<0.05, significant in comparison to the LFD control. 
#, p<0.05, significant in comparison to the HFD control. $, p<0.05, significance 
between PFOS and PFNA within the same diet (i.e. L/HPFOS vs L/HPFHxS). 
&, p<0.05, significance between diet treatment within the same compound (i.e. 
LPFAS vs HPFAS  
 



















# 2.1±0.2#$ 3.3±0.5$ 3.6±0.2* 3.1±0.5 3.8±0.3* 
Liver:B
W % 5.0±0.8
 4.7±0.3$ 7.6±1.4# 6.6±0.4 5.7±0.8 7.6±0.3 
WAT:B
W % 5.9±0.4


















Table 2.  Lipid Accumulation Pathology Scores 
 
The lipid accumulation score assigned out of total mice per group. Assigned 
scores ranged from 0 to 4, with 0 being the least and 4 the most severe. N = 
5-6. Statistical analysis was performed using Kruskal–Wallis test to derive 
ranks followed by Dunn's multiple comparison test for multiple comparisons 
using GraphPad Prism software v8.2.0 (La Jolla, CA). *, p<0.05, significant in 
comparison to the LFD control. #, p<0.05, significant in comparison to the HFD 
control. $, p<0.05, significance between PFOS and PFNA within the same diet 
(i.e. L/HPFOS vs L/HPFHxS). &, p<0.05, significance between diet treatment 
within the same compound (i.e. LPFAS vs HPFAS).
Scores LFD LPFHxS LPFOS HFHC HPFHxS HPFOS 
0 0/6 1/5 0/6 0/6 0/6 0/6 
1 1/6 1/5 1/6 0/6 0/6 0/6 
2 2/6 3/5 3/6 3/6 0/6 1/6 
3 3/6 0/5 2/6 3/6 5/6 3/6 
4 0/6 0/5 0/6 0/6 1/6 2/6 




Table 3. Liver Inflammation Pathology Scores 
 
Liver inflammation scores per mouse within each treatment group (n=5-6). 
Assigned scores ranged from 0 to 4, with 0 being the least and 4 the most 
severe. Scores were converted to ranks using the Kruskal–Wallis test. 
Significance was calculated by one-way ANOVA test for multiple comparisons 
using GraphPad Prism software v8.2.0 (La Jolla, CA). *, p<0.05, significant in 
comparison to the LFD control. #, p<0.05, significant in comparison to the HFD 
control. $, p<0.05, significance between PFOS and PFNA within the same diet 
(i.e. L/HPFOS vs L/HPFHxS). &, p<0.05, significance between diet treatment 
within the same compound (i.e. LPFAS vs HPFAS).  
Treatment LFD LPFOS LPFHxS HFHC HPFOS HPFHxS 
0 0/6 0/6 1/5 0/6 0/6 0/6 
1 1/6 1/6 1/5 0/6 0/6 0/6 
2 2/6 3/6 3/5 3/6 1/6 0/6 
3 3/6 2/6 0/5 3/6 3/6 5/6 
4 0/6 0/6 0/5 0/6 2/6 1/6 




Table 4. Biliary Hyperplasia Pathology Scores 
 
 
The biliary hyperplasia score assigned out of total mice per group. Assigned 
scores ranged from 0 to 4, with 0 being the least and 4 the most severe. N = 
5-6. Statistical analysis was performed using Kruskal–Wallis test to derive 
ranks followed by Dunn's multiple comparison test for multiple comparisons 
using GraphPad Prism software v8.2.0 (La Jolla, CA). *, p<0.05, significant in 
comparison to the LFD control. #, p<0.05, significant in comparison to the HFD 
control. $, p<0.05, significance between PFOS and PFNA within the same diet 
(i.e. L/HPFOS vs L/HPFHxS). &, p<0.05, significance between diet treatment 




 LFD LPFOS LPFHxS HFHC HPFOS HPFHxS 
0 6/6 1/6 3/5 6/6 2/6 1/6 
1 0/6 2/6 2/5 0/6 4/6 5/6 
2 0/6 3/6 0/5 0/6 0/6 0/6 
3 0/6 0/6 0/5 0/6 0/6 0/6 
4 0/6 0/6 0/5 0/6 0/6 0/6 




Table 5. PFOS and PFHxS Partitioning  
 
Male C57BL6 mice were fed with either a low fat diet or a high fat high 
carbodydrate diet with or without PFOS or PFHxS (0.0003% w/w in feed) for 12 
weeks. After necropsy, PFOS and PFHxS were extracted from liver and serum 
then quantified using LC-MS/MS. All control groups exhibited PFOS and PFHxS 
concentrations below the lower limit of quantification (LLOQ). Likewise, no 
quantifiable cross-contamination between PFOS and PFHxS treated groups 
was found. PFHxS partitioned to the serum preferentially in comparison to 
PFOS. Calculations were done using a one-way ANOVA followed by Fisher’s 
LSD test.  All values are means ± SEM; n = 1-6. $, p<0.05, significance between 
PFOS and PFNA within the same diet (i.e. L/HPFOS vs L/HPFHxS. &, p<0.05, 








 LPFHxS LPFOS HPFHxS HPFOS 
Liver 
(𝛍𝛍g/g) 
21.7±1.8$ 105.1±15.1$ 6.36±1.7$ 97.8±7.0$ 
Serum  
(𝛍𝛍g/mL) 




Sample Absorbance (nm) Concentration (ug) 
1 0.5182 2.05 
2 0.4911 1.91 
3 0.4943 1.93 
4 0.476 1.83 
5 0.5225 2.07 
6 0.4909 1.91 
7 0.452 1.71 
8 0.4813 1.86 
9 0.4554 1.73 
10 0.4535 1.72 
11 0.4478 1.69 
12 0.4879 1.89 
13 0.4994 1.95 
14 0.4782 1.84 
15 0.438 1.64 
16 0.4867 1.89 
17 0.4868 1.89 
18 0.4836 1.87 
19 0.5636 2.28 
20 0.8733 3.86 
21 0.8326 3.65 
22 0.8272 3.63 
23 0.8338 3.66 
24 0.8616 3.80 
25 0.8574 3.78 
26 0.8514 3.75 
27 0.852 3.75 
28 0.8602 3.79 
29 0.7129 3.04 
30 0.8195 3.59 
31 0.8458 3.72 
32 0.8401 3.69 
33 0.8537 3.76 
34 0.8586 3.79 
35 0.8106 3.54 
 
Supplemental Table 1.  Lipid phosphorus assay. Lipids extracted from blood 
samples were analyzed for inorganic phosphorus content based on analysis of 
standards ranging from 1 ug to 5 ug at λ=590 nm. Concentrations of samples were 



















































































































































Supplemental Table 2.  LIPEA pathway analysis. List of results from lipid indicators 
LFD and LFD with PFAS (LPFOS and LPFHxS) exposure and HFHC and HFHC with 






Supplemental Table 3. Custom Quantigene Panel. Gene names and functions 
selected for targeted expression analysis. The chosen genes are involved in lipid 
accumulation and transport, lipid metabolism, oxidative stress, and inflammation.                     
GENE NAME FUNCTION 
Acaca Acetyl-CoA Carboxylase Alpha enzyme that catalyzes the rate-limiting step in fatty acid 
synthesis 
Acot2 Acyl-CoA Thioesterase 2 regulation of lipid metabolism/intracellular levels of free fatty 
acids 
Ccl2 C-C Motif Chemokine Ligand 2 chemotactic factor that attracts monocytes and basophils 
Cd36 Cluster Determinant 36 involved in long chain fatty acid uptake 
Cidea Cell Death Inducing DFFA Like Effector A binds to lipid droplets and regulates their enlargement 
Cpt1 Carnitine Palmitoyltransferase 1 catalyzes mitochondrial uptake of fatty acids for beta-oxidation 
Csf2r𝜶𝜶 Colony Stimulating Factor 2 Receptor Alpha cytokine which controls the production, differentiation, and 
function of granulocytes and macrophages 
Cyp Cytochrome P450 family oxidation of fatty acids, xenobiotics, etc. 
Ehhadh Enoyl-CoA Hydratase And 3-Hydroxyacyl 
CoA Dehydrogenase 
enzyme in fatty acid beta-oxidation pathway 
Fabp Fatty Acid-Binding Protein  role in fatty acid uptake, transport, and metabolism 
Fas Fatty Acid Synthase  catalyzes fatty acid synthesis 
Gclc Glutamate-Cysteine Ligase Catalytic 
Subunit 
the first rate-limiting enzyme of glutathione synthesis 
Gstm3 GSTM3 glutathione S-transferase mu 3 mediates uptake and detoxification of both endogenous 
compounds and xenobiotics 
Hmgcs1 3-Hydroxy-3-Methylglutaryl-CoA Synthase 1 catalyzes the formation of HMG-CoA 
Lpl Lipoprotein lipase functions as a triglyceride hydrolase and ligand for lipoprotein 
uptake 
Mttp Microsomal triglyceride transfer protein Important function in the hepatic export of lipid rich particles 
such as VLDL 
Nqo-1 NAD(P)H Quinone Dehydrogenase 1 involved in detoxification pathways 
Nrf2 Nuclear Factor Erythroid 2–Related Factor 2 transcription activator that up-regulates genes in response to 
oxidative stress 
Ppar-𝜶𝜶 Peroxisome Proliferator-Activated Receptor 
Alpha 
Transcription factor that regulates the beta-oxidation pathway 
of fatty acids 
Ppar-𝜸𝜸 Peroxisome Proliferator-Activated Receptor 
Gamma 
nuclear receptor that activates the peroxisomal beta-oxidation 
pathway of fatty acids 
Scd1 Stearoyl-CoA Desaturase involved in fatty acid biosynthesis 
Slc271a Solute Carrier Family 27 Member 1A long-chain fatty acid (LCFA) uptake into the cell 
Sod1 Superoxide Dismutase 1 eliminates radicals which are toxic to biological systems 
Srebf1 Sterol Regulatory Element Binding 
Transcription Factor 1 
transcriptional activator for lipid homeostasis, regulates fatty 
acid and cholesterol synthesis 
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Supplemental Figure 1. Food consumption over the course of the study. 
Statistical significance was calculated using one-way ANOVA where a: 
significant from the LFD control, b: significant from the HFHC control, c: 
significance between PFOS and PFHxS within each diet and d: significance 
between diet within each compound. A) Food consumption is expressed as 
average consumption per mouse per day over time. Each point represents 
average food consumed ± SEM. B) Overall average food consumption per 









Supplemental Figure 2. Glucose tolerance is modulated by HFHC feeding. 
A glucose tolerance test (GTT) was conducted following 25 weeks of PFOS 
exposure. After a 6 hr fast, 1 mg/kg glucose was administered via intraperitoneal 
injection, and blood glucose was measured after 0, 15, 30, 45, 60, 90, 120, and 



































Supplemental Figure 3. PFAS induce a unique lipidomic signature relative 
to LFD control. A) Supervised Partial Least Discriminant Analyses indicate 
discrimination between LFD control and LFD with PFAS compounds based on 
the lipidome. B) & C) Cross validation (CV) analyses (10-fold CV method) 




























Supplemental Figure 4. PFAS induce a unique lipidomic signature relative 
to HFHC control. A) Supervised Partial Least Discriminant Analyses indicate 
that it is possible to discriminate between HFHC control and HFHC with PFAS 









SUMMARY AND CONCLUSIONS 
 
Non-alcoholic fatty liver disease is described by the American Liver Foundation 
(ALF), as the excessive accumulation of fats in the liver in the absence of alcohol 
use(Liver Disease Statistics - American Liver Foundation). Hepatic steatosis can 
trigger liver inflammation and fibrosis, progressing to a disease state known as 
non-alcoholic steatohepatitis (NASH). If left unchecked the scarring can progress 
to a life-threatening condition known as cirrhosis(Pathophysiology of Non 
Alcoholic Fatty Liver Disease). According to the American Liver Foundation, up to 
30 – 40% of adults and 10% of children in the US are currently afflicted with 
NAFLD (Liver Disease Statistics - American Liver Foundation). This silent 
disease is difficult to diagnose due to the absence of symptoms and the lack of 
non-invasive and reliable diagnostic tests. Currently, diagnosis is best achieved 
through an invasive liver biopsy and no FDA approved drug is available on the 
market for treatment (El-Agroudy et al., 2019). While obesity, metabolic 
syndrome, and diabetes are all known risk factors for NAFLD, the role of 
environmental toxicants as risk factors is not well understood (Duseja and 
Chalasani, 2013). 
Perfluoroalkyl substances (PFASs), a family of environmental toxicants, have 
become ubiquitous in the environment and the human population (Olsen et al., 
2017). These long-chain fluorinated structures are extremely resistant to 
degradation leading to their accumulation in water sources, dust, and even 
ambient air (Hu et al., 2016; Winkens et al., 2018; Barber et al., 2007). PFASs 




others, perfluorooctanesulfonic acid (PFOS), perfluorohexanesulfonic acid 
(PFHxS), and perfluorononanoic acid (PFNA) (Mamsen et al., 2019; Olsen et al., 
2017). PFOS, PFNA, and PFHxS are slow to excrete from the human body, with 
half-lives spanning several years (Li et al., 2018; Zhang et al., 2013). Once in the 
body, these PFASs distribute mainly to protein rich body compartments such as 
serum and liver (Bogdanska et al., 2011). This distribution pattern leads to 
relatively high exposure of PFASs to hepatocytes, increasing potential risk for 
hepatic toxicity. While the lifetime effects of chronic PFAS exposure remain 
under investigation, human studies have associated PFAS exposure with 
elevated serum cholesterol (Nelson et al., 2010) and biomarkers of liver injury 
(Gallo et al., 2012). PFASs have been shown to augment lipid accumulation and 
steatosis in the liver in human hepatocytes (Bjork et al., 2011; Rosen et al., 2013) 
and rodents (Wan et al., 2012; Das et al., 2017). 
 There is a clear lack of knowledge concerning the long-term effects of low-level 
exposure to common PFASs, in combination with dietary risk factors, and their 
potential role in the increasing incidence of NAFLD in the global population 
(Younossi et al., 2018). Understanding the potential health effects of PFAS 
members plays a vital role in guiding the federal regulations that determine 
advisory levels in drinking water. Due to emerging toxicity data, the health 
advisory for PFOS in drinking water was lowered to 70ppt in 2016. This health 
advisory level was derived from the no observable adverse effect level (NOAEL) 
doses observed in rodent toxicity studies evaluating the effect of PFOS on pup 




2016). PFAS manufacturing companies, such as 3M, have voluntarily removed 
PFOS from manufacturing, however, PFHxS and PFNA are serving as 
replacements in manufacturing and consumer products. Despite potential for 
similar toxicity, PFHxS and PFNA remain unregulated. Moreover, PFOS, PFNA, 
and PFHxS continue to be prevalent in humans, wildlife, and the environment 
today (Guelfo et al., 2018). There is a critical need for a better understanding of 
PFASs’ hepatotoxicity at an exposure relevant dose.   
In Manuscript 1, the subchronic hepatic toxicity of feed containing 0.0003% 
PFOS or PFNA was investigated with or without a high fat diet in C57BL6 mice. 
Liver pathology was assessed by H&E staining and the hepatic mechanisms 
were explored using a combination of transcriptomics and proteomics. 
Transcriptomics was performed by ST 2.0 microarray at Brown University. 
Transcriptome analysis console (TAC) software from Affymetrix and Ingenuity 
Pathway Analysis (IPA) software from Qiagen were used to filter, sort, and 
analyze the data. Targeted gene expression was measured using an Affymetrix 
Quantigene Plex Panel on a Biorad Bioplex 2.0. Proteomics was performed by 
SWATH-MS conducted on a quadrupole-time-of-flight mass spectrometer (ESI-
QTOFMS). The data was analyzed using proteomic software MaxQuant, 
Perseus, and Skyline. LCMS detection of PFASs in serum and liver was 
performed in house on a QTRAP® 4500 LC-MS/MS System. In Manuscript 2, the 
impact of a high fat and high carbohydrate diet on hepatic steatosis and 
progression to NASH in the presence of chronic exposure low dose, 0.0003% 




expression were performed as they were in Manuscript 1. In addition, shotgun 
lipidomics was measured by electrospray ionization-mass spectrometry (ESI-
MS).  
A major take away from the work encompassed is that dietary fat or composition 
can dramatically alter the impact that PFASs exert on the onset and progression 
of hepatic steatosis and NAFLD. This revelation will be critical to better assessing 
the public health risk that PFAS may pose in modulating diet induced fatty liver 
disease. The second major conclusion from this work is that the replacement 
compounds PFNA and PFHxS produce unique hepatic expression signatures 
and partitioning profiles but exert similar effects to PFOS on liver pathology. 
Federal health advisories for PFNA and PFHxS have yet to be released, despite 
the many structural and behavioral similarities to the known hepatotoxicant 
PFOS. The ability of PFOS, PFHxS, and PFNA to significantly alter a disease 
outcome at a PFOS non-observable adverse effect level (NOAEL) may be cause 
for concern. Given that the replacement compounds, PFHxS and PFNA, do not 
seem to mitigate hepatic toxicity in relation to PFOS, it is possible that class level 
regulation of the PFAS family may be justified.  
The work presented here is focused on characterizing PFAS-diet interactions in 
the context of NAFLD. However, the ‘omic (transcriptomic, proteomic, and 
lipidomic) data sets that have been generated throughout the course of this work 
could serve as a basis to form or answer additional scientific questions outside 
the context of NAFLD. The behavior and exact mechanisms of PFAS in vivo 




further explored to gain additional insight into the hepatic mechanisms PFAS 
modulated NAFLD. For instance, the functional role, biological consequences, 
and serum biomarker potential of the identified modulated sera lipid moieties 
should be further explored. In addition, the structural similarities and differences 
and their mechanistic implications between PFOS and PFHxS or PFOS and 
PFNA could be mined further within transcriptomic and proteomic datasets. The 
transcriptomic dataset generated in manuscript 1 is available on the GEO  
database under accession number GSE138602. The proteomic datasets will be 
publicly accessible under the ProteomeXchange Consortium. The manuscript 1 
dataset can be found using the identifier PXD015977 and manuscript 2 under 
identifier PXD015976. It is my hope that the big data, ‘omic datasets 
characterized within may provide a useful springboard for future studies to further 
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Background: A diet rich in fats and sugar can promote obesity, which is linked to 
increased systemic inflammation and adverse health outcomes. In the brain, this 
inflammatory stimulus activates and promotes recruitment of microglia a key 
component in the pathogenesis of neurodegenerative diseases. Poor diet can also 
induce and augment the progression of non-alcoholic fatty liver disease (NAFLD) 
via increased systemic inflammation, which is also linked to poorer 
neurodegenerative outcomes. Pomegranate extract (PE) could be a potential 
source of beneficial phytonutrients capable of mitigating these inflammatory 
processes.    
Methods: Male C57BL/6 mice were fed either a high fat diet (HFD) (45% kcal from 
fat) or a standard grain free rodent diet (LFD) (10% kcal from fat) with or without 
PE at 1% w/w for 12 weeks. Mice were sacrificed following 12 weeks, and liver 
pathology and liver lipid moieties were examined. Whole livers and hippocampi 
were excised for multiplexed gene expression analysis of inflammatory, NAFLD, 
and neurodegenerative disease associated genes. 
Results: Mice fed a HFD for 12 weeks exhibited elevated expression of both pro- 
and anti-inflammatory cytokine/growth factors, neurodegenerative genes, and 
hepatic lipid associated genes. In mouse hippocampi, HFD+PE mice showed 
significant reduction in gene expression of a number of key pro-inflammatory 




In mouse livers, PE significantly reduced lipid accumulation scores and key lipid 
regulating genes, such as Cd36, Fas, Acot2, Slc27a1, and Cyp4a14, within a HFD.  
Conclusions: In the hippocampus, immune cell recruitment and differentiation for 
tissue repair, leptin signaling and neurofibril processing via the MAPT-GSK3β-APP 
axis are significantly modulated by PE. In the liver, PE played a preventative role 
against the onset and potential inflammatory progression of NAFLD. PE 
administration exerted protective effects against lipid accumulation, fatty acid 
uptake and metabolism, and hepatic inflammation.  
 
Background 
Dietary factors augment the onset and progression of the most common diseases 
burdening global health today: type II diabetes mellitus (T2DM), cardiovascular 
disease, non-alcoholic fatty liver disease (NAFLD), and numerous forms of 
neoplasias (1). Poor diet, such one rich in saturated fats and starches, has been 
linked to the generation of low grade inflammation systemically, exerting adverse 
effects on multiple organ systems within the body(2,3). The most common liver 
disease, NAFLD, and neurodegenerative diseases, such as  Alzheimer’s, share 
obesity as a risk factor (4,5). Treatments for these diet-associated disorders 
include lipid/cholesterol reducers such as statins (atorvastatin, simvastatin), insulin 
sensitizers such as metformin and thiazolidinediones (e.g. rosiglitazone), alpha-
glucosidase inhibitors, fibrates, non-steroidal anti-inflammatory drugs (NSAIDs) 




number of undesirable side effects, have been substituted for less detrimental  
forms of medicine such as  diet restrictions, bariatric surgery, and exercise (6,7).  
The progressive loss in neuron function and viability is associated with aging and 
neuroinflammation (13). Neuroinflammation is largely governed by microglia, the 
resident immune cells of the brain, (14) and has been associated with the etiology 
of AD and PD in rodents and patients  (15,16). One common site of 
neuroinflammation is the hippocampus, which is responsible for maintaining basic 
cognitive function and memory.  The hippocampus is one for the first regions of 
the brain to be affected by an inflammatory insult (17,18). The hippocampus is also 
a major site for the accumulation of neurotoxic neurofibrillary plaques and tangles 
(19,20).  
Non-alcoholic fatty liver disease (NAFLD), is a spectrum disease that affects over 
30% of the American population (21). The onset of fatty liver is believed to be 
initiated by an excess of dietary fatty acids. In the presence of hepatic 
inflammation, the disease progresses to non-alcoholic steatohepatitis (NASH) and 
prolonged inflammation can cause scarring or fibrosis of the liver. In severe cases 
there is a life-threatening loss in hepatic function, known as cirrhosis (22). By 
feeding mice a diet rich in saturated fats and refined sugars, this diet promotes  
physiologic features exemplified by obese individuals consuming a  “Western” diet  
as seen in North America and Europe (23).  
Natural products have been considered for patients with metabolic syndrome 
(MetS) on the basis of safety and cost (24–26). Numerous in vitro, in vivo, and 




have been published. However, the underlying molecular mechanisms of natural 
products and traditional herbal medicines (e.g. Ayurveda and traditional Chinese 
medicine) are less defined in the brain. Polyphenols, represent a significant portion 
of the natural products commonly studied in age-related disease states and cancer 
(27–30).   One source of these polyphenols is an extract derived from pomegranate 
(Punica granatum). A commercially available pomegranate extract (PE), which is 
standardized to its major chemical constituent, punicalagin (PA), has also been 
studied for its anti-bacterial, anti-inflammatory and anti-diabetic properties (31–34). 
PA and its metabolite, ellagic acid (EA), are known to be metabolized by specific 
gut microbes and transformed to a class of significantly studied and therapeutically 
valuable compounds known as urolithins (35,36). The anti-inflammatory capacity 
and mechanisms of PE constituents have also been investigated using an in vitro 
model of neurodegeneration with murine microglia and human neurons (37,38).  
Our group has previously measured the ability of PE to combat the effects of AD 
in an Beta-amyloid transgenic mouse model (39). Herein, the ability of PE to 
modulate the pro-inflammatory effects of a western style diet in the brains and 
livers of wild type C57BL/6 mice is explored. 
 
Materials and Methods 
Animals and study conditions. C57BL/6 mice were acquired from Jackson Labs 
(Bar Harbor, ME USA) and acclimated for at least two weeks. Mice were then 
weight paired and housed four mice per cage. Mice were housed under 12-hour 




were fed either a standard grain-free low fat diet (LFD) (n=8) (Research Diets Cat# 
D12450B, New Brunswick, NJ), or a high fat diet where 45% of calories were 
derived from fat (HFD) (n=8) (Research Diets Cat# D12451, New Brunswick, NJ).  
PE was provided by Verdure Sciences and was incorporated directly into 
powdered LFD (n=4) or HFD (n=4) (1% w/w). Body weights and food consumption 
were monitored weekly. Following 12 weeks of diet administration, all mice were 
anesthetized using isoflurane and sacrificed by cervical dislocation. Tissues were 
immediately harvested and snap frozen in liquid nitrogen. Brains were separated 
into cortex, cerebellum, and hippocampus regions. Gross liver weight was 
recorded prior to sectioning in 10% formalin for histology. The remaining liver was 
snap frozen for downstream analysis. This study and its protocols were approved 
by and conducted in accordance with the University of Rhode Island Institutional 
Animal Care and Use Committee (IACUC) (Approval # AN09-07-004). 
 
Hepatic lipid isolation and analysis. Liver lipids were isolated from approximately 
50 mg of liver tissue using a chloroform-methanol extraction method described by 
(40). Triacylglyceride (TAG) and total cholesterol, were measured using kits from 
Pointe Scientific (Ann Arbor, MI USA). Total non-esterified free fatty acids (NEFA) 
were quantified using a kit from Wako Chemicals (Richmond, VA USA).  
 
Nucleic isolation from tissue. Whole hippocampi and livers were isolated at the 
time of necropsy and snap frozen for nucleic acid isolation. Tissue was 




added directly to a Trizol Spin Column (Zymo Research, San Diego, CA USA) to 
isolate nucleic acids according to the manufacturer’s protocol. RNA concentration 
and quality were then determined using a spectrophotometer (Nanodrop, Thermo 
Fisher, Waltham, MA USA)  
 
Gene expression analysis. Gene expression analysis was conducted on RNA 
samples using a custom QuantiGene Luminex xMAP Gene Expression panel 
(Thermo Fisher, Waltham, MA USA). The multiplex assay was performed 
according to the manufacturer’s protocols and mean fluorescence intensity (FI) 
was quantified using a Bio-rad Bio-plex 200 instrument (Hercules, CA USA). 
Hippocampi genes of interest in inflammatory, neurodegenerative, and antioxidant 
response processes were Il-1α, Il-1β, Il-2, Il-3, Il-4, Il-6, Il-7, Il-9, Il-10, Il-11, Il-13, 
Il-15, Il-16, Il-18, Il-19, Ifnα, Ifnγ, Tnf, Cd38, Cd70, Fasl, Mif, Csf1, Cd40lg, Lepr, 
Cd36, Mapt, Gsk3β, App, Pparγ, Itgam, Sting, Nos2, Sod1, and Nfe2l2.  The 
expression of transcripts involved in inflammation, lipid uptake, lipid metabolism, 
and lipid regulation were measured in whole liver tissue using a second custom 
QuantiGene panel. Hepatic genes of interest included Acaca, Acot2, Ccl2, Cd36, 
Cpt1a, Cpt1b, Csf2ra, Cyp4a14, Ehhdh, Gstm3, Fabp1, Cidea, Fabp4, Fas, 
Gapdh, Gclc, Gpam, Gusb, Mttp, Hmgsc1, IL6, Lpl, Nrf2, Nqo1, Pparα, Pparγ, 
Scd1, Slc27a1, Sod1, Srebf1, Tnfα, Actb, Hprt, and Eif3f.  
 
Statistical analysis. All gene expression data shown as mean fluorescence 




variance (ANOVA) and Dunnett’s for multiple comparisons. Body weight, tissue 
weight, and hepatic lipid data are shown as mean ± SEM and compared for 
statistical significance using ANOVA and fisher’s exact test where p< 0.05 was 
statistically significant.  Calculations were performed using Graphpad Prism 
(Graphpad Prism Software for Windows Ver 8.0, La Jolla, CA USA). 
 
Results 
PE supplementation attenuated high fat diet fed white adipose, liver, and 
body weight gains.  
Final body weights of HFD mice following 12 weeks of a high fat diet exposure 
were increased by approximately 12 grams compared to LFD mice (Figure 1A). 
Additionally, the HFD induced liver weight by 15% (Figure 1B) and WAT weight by 
50% compared to controls (Figure 1C). The HFD-induced increase in weight was 
not observed in the HFD-PE mice, which had final weights similar to LFD fed 
controls.   
 
PE supplementation decreased hepatic total lipid, triacylglyceride, and non-
esterified free fatty acid levels in LFD and HFD mice and improved diet-
induced liver injury. 
NAFLD is characterized by increased deposition of fats in liver (41), therefore 
hepatic lipid content was determined. The HFD increased total hepatic lipid, TAG, 
and FFA content significantly compared to LFD controls. Interestingly, the total 




to the LFD controls (Figure 2A). H&E staining revealed that the HFD fed mice 
developed marked macrovesicular steatosis, a signature of fatty liver. PE 
supplementation within a HFD clearly protected against lipid vacuolization, 
resulting in a healthy liver phenotype similar to the LFD controls (Figure 2B).  
 
PE attenuates hepatic expression of key genes involved in the onset and 
progression of NAFLD.  
PE suppressed the hepatic expression of nuclear receptors, Pparα and Pparγ, as 
well as their target genes related to lipid synthesis, transport, and metabolism in 
the liver. PE supplementation caused significant suppression of fatty acid 
synthesis genes, Fas and Scd1 (Figure 3A). Within both the LFD and HFD, PE 
significantly suppressed fatty acid uptake genes, Fabp1 and Slc27a1. Within the 
HFD, PE further attenuated fatty acid transporters CD36 and Fabp4 (Figure 3B). 
In addition to uptake, PE modulated the mitochondrial fatty acid beta oxidation 
pathway. PE administration resulted in suppressed transcription of fatty acid 
metabolism associated genes, Cpt1a, Cpt1b, Ehhadh, and Cyp4a14 (Figure 3C). 
Furthermore, PE may prevent inflammatory progression of fatty liver via 
suppression of hepatic pro-inflammatory genes, Tnfα, IL6, Csf2ra, and Ccl2 
(Figure 4D).  
 
PE attenuates the gene expression of key Interleukins and inflammatory 




The HFD fed increased the relative abundance of multiple interleukins (1, 2, 3, 4, 
6, 7, 9, 10, 11, 13, 15, 16, 18, 19) and interferons (α and γ) in hippocampus 
compared to the LFD diet (Figure 4). Co-treatment of PE and HFD prevented high 
fat induction of Il-1α, Il-1β, Il-7, Il-11, and Tnf gene expression in the hippocampi 
tissue, yielding expression levels similar to the LFD controls. Interestingly, Il-2, Il-
3, and Il-13 were upregulated by 29.6%, 30.3% and 114.7% respectively when 
comparing HFD to HFD+PE.  
 
PE supplementation modulates Alzheimer ’s disease associated genes but 
augments antioxidant response and reactive nitrogen species  hippocampal 
gene expression in HFD mice. 
In this study, the HFD diet elevated the levels of some transcripts commonly 
associated with Alzheimer’s disease: microtubule associated protein tau 
(Mapt/Tau), glycogen synthase kinase 3 Beta (Gsk3β), and amyloid precursor 
protein (App) (Figure 5A).  In general, in mice fed HFD-PE, this induction was not 
observed, and expression was similar to LFD controls.   
The HFD increased Nitric oxide synthase 2 (NOS2) and super oxide dismutase 1 
(SOD1) by 76% and 40%, respectively.  PE supplementation LFD mice increased 
Nos2 gene expression by 43.4% as compared to the LFD control mice (Figure 
5A). Another major antioxidant response gene, Nfe2l2 (commonly known as Nrf2), 
was upregulated in the hippocampus by 61.1% in HFD fed mice as compared to 






PE significantly abrogates Leptin Receptor and Fatty acid transport 
Receptor, CD36, in Hippocampi of HFD fed mice.   
The HFD increased Cd38, Cd70, FAS ligand, Cd40 ligand by approximately 135%, 
288%, 185%, and 89% respectively as compared to LFD control mice (Figure 5B). 
Macrophage/microglial associated genes, macrophage infiltration factor (MIF) and 
colony stimulating factor 1 (CSF1) were also significantly upregulated by 46.4% 
and 74.8% respectively in the HFD fed mice. PE supplementation to LFD 
increased the hippocampal gene expression of both Mif and Csf1 by 26.2% and 
42.7% respectively.  Interestingly, leptin receptor and Cd36, two major fatty acid 
transport associated genes, were also markedly increased in HFD fed mice by 
192.1% and 82.8% respectively. PE supplementation in HFD reduced the gene 
expression of Lepr and Cd36 by 41% and 23.7% in the hippocampus respectively. 
Moreover, HFD+PE mice decreased Lepr expression to levels similar to LFD 
control mice (7.13 MFI ± 0.94).  
 
Discussion 
PE reduced diet-induced weight gain. Following 12 weeks of dietary intervention, 
body, white adipose tissue, and liver weights were significantly increased as a 
result of exposure to high fat diet (45% kCal from fat) as compared to their low-fat 
controls (10% kCal from fat). PE supplementation within the HFD (HFD-PE) 




measures being similar to the LFD controls.  These findings are consistent with 
previous reports that PE has anti-obesogenic properties (42). 
Several groups have demonstrated the hepatoprotective actions of PE against 
NAFLD in both rodent and human models(43,44)  This study recreated these 
findings in a C57BL6/J model and further explored the mechanistic effect of PE on 
hepatic gene expression. Previous papers have identified PPARα/PPARγ 
modulation by the PE constituent, punicic acid, as the underlying mechanism of 
PE’s protective action against metabolic syndrome and NAFLD (45,46) Likewise, 
in this study we saw significant down regulation of both PPARγ/PPARα and their 
target genes (Cd36, Fabp1, Cpt1a, Cpt1b, Fas, etc.).  
One potential mechanism of PE’s protective effect is reduced fatty acid uptake into 
the liver. Hepatic fatty acid accumulation is hypothesized to be a critical initiating 
event in the pathogenesis of NAFLD (22). PE significantly suppressed fatty acid 
uptake genes, Fabp1, Slc27a1, Cd36, and Fabp4, thereby potentially limiting the 
hepatic influx of fatty acids. This diminished uptake was also accompanied by a 
decrease in fatty acid synthesis gene, potentially further contributing to a hepatic 
reduction in free fatty acids. This proposed mechanism is further supported by 
diminished hepatic fatty acid content observed in PE supplemented mice 
compared to the HFD controls. Furthermore, there was no induction of the 
mitochondrial fatty acid beta oxidation pathway, largely regulated by PPARα. 
Relative to the HFD, PE actually suppressed genes related to fatty acid 
metabolism in the liver mitochondria, such as, Cpt1a, Cpt1b, Ehhadh, and 




of fatty acid metabolism.  This finding further supports the theory that the 
diminished fatty acid content is attributable to decreased uptake and synthesis 
rather than induced fatty acid metabolism in PE-supplemented mice. 
PE may play a protective role against the inflammatory progression of NAFLD in a 
murine model of diet-induced obesity. Poor diet is known to induce a pro-
inflammatory response in the body (2,3) Previous work has clearly demonstrated 
the anti-oxidative action of PE in the liver (47,48) Likewise, in this study PE 
significantly dampened expression of Nrf2 mediated oxidative stress response 
genes. Furthermore, we observed an expected suppression in hepatic pro-
inflammatory genes: Tnfα, IL6, Csf2ra, and Ccl2. The later stages of fatty liver, 
NASH and cirrhosis, are known to be inflammation mediated (22). By protecting 
against diet-induced pro-inflammatory gene expression in the liver, PE may 
suppress hepatic inflammation and therefore reduce the risk of NAFLD 
progression. 
In the case of neurodegenerative diseases, studies have shown that specific 
dietary components may contribute to the weakening of the blood-brain barrier and 
ultimately the progressive activation of microglia (23,49). Over time, the capacity 
of microglia to respond to pathogen-associated molecules (i.e. lipopolysaccharide 
or bacterial DNA) or damage-associated molecules (i.e. nucleic acids from 
necrotic/apoptotic cells) weakens and thus to compensate, more macrophages are 
recruited further secreting inflammatory mediators (13,14). This  increase of 
inflammatory stimuli leads to the necrosis and apoptosis of neurons and depending 




In the hippocampus, inflammatory mediators, Il-1α and Il-1β were elevated in HFD 
mice but modulated in PE treated HFD mice. Il-1 is also implicated in signaling for 
tissue repair by stimulating helper T-cells (Th17) (51,52).  Il-7 which is heavily 
involved in B-cell proliferation, T-cell survival, and stimulation of interleukins in 
monocytes, was augmented in HFD but abrogated in HFD-PE mice (53,54).  Il-11, 
which is responsible for protecting epithelial and connective tissue, stimulating 
neuronal development, was upregulated in HFD mice but significantly attenuated 
in LFD+PE and HFD+PE mice.  Tnfα was also significantly overexpressed in HFD 
fed mice but also attenuated to levels similar to LFD control mice. These findings 
suggest that PE modulates the immune responses associated with prolonged 
exposure to a HFD (15,50).  
Consistent with findings from other long-term diet-induced obesity rodent studies, 
Tau, Gsk3β, and App, were significantly overexpressed in the hippocampi of mice 
fed a HFD as compared to mice fed a standard LFD (23,55,56).  PE’s effect within 
the hippocampus led to the reduction in gene expression of neurotoxic peptides. 
Moreover, our previous studies evaluating these same endpoints but in aged, 
transgenic  β-amyloid producing mice, demonstrated decreasing trends (39).  
Interestingly, PE significantly attenuated hippocampal Lepr as compared to HFD 
control mice. Apart from supporting cognitive function, Lepr is implicated in 
neuronal synaptic plasticity and the food reward response (57). While serum leptin 
levels were not measured, literature suggests that low leptin levels in the brain, 




In the hippocampus, neuroinflammatory and neurodegenerative processes are 
heavily influenced by leptin signaling, and, according to Bonda and colleagues, the 
result of obesity rather than age (61). Evidence from other in vivo studies suggests 
that leptin resistance in Alzheimer’s disease is due to hyperphosphorylation of tau 
by GSK3β and aggregation of neurofibrillary tangles (NFTs) (59,60). In 
hippocampal neurons, aberrant leptin signaling causes cognitive deficits over time 
(60).   
The addition of PE to the HFD significantly reduced the expression of these AD-
associated genes and significantly modulated Lepr signaling as compared to LFD 
control mice. Additional rodent studies are further needed to confirm the 
observation that leptin signaling modulation leads to weight loss and an 
improvement in neuron health in HFD+PE fed mice.  
PE also augmented hippocampal gene expression in PE+LFD mice of Il-1 β, Il-2, 
Il-3, Il-13, Il-19, Nos2, Cd38 and Cd70 as compared to LFD mice.  Il-1β, is needed 
to maintain neuronal synaptic plasticity (51). The expression of the interleukins 2 , 
3, 13, and 19 are observed during an influx and activation of both lymphocytes and 
microglia which may be beneficial and prevent neuronal damage (62,63).  Despite 
gene expression being elevated, actual protein levels may or may not correlate 
indicating PE may exert these effects by binding to specific transcription regulatory 
factors.  
The constituents of pomegranate and related extracts have been previously  
evaluated  by a number of groups in rodents and humans(64–70). Specifically,  PE 




administration, Punicalagin is almost entirely metabolized to ellagic acid in the 
stomach and further metabolized in the small and large intestine by key gut 
microbes (e.g. Gordonibacter urolithinfaciens) into urolithins(65,71,72). Urolithin A 
(UA),urolithin B(UB), methyl urolithin A (mUA),  methyl urolithin B (mUB), and 
several urolithin analogs have been found in rodents and humans following 
pomegranate or ellagitannin exposure(36,65,71). However, inter-individual  
variations or “metabotypes” in humans due to the  presence or absence of urolithin 
producing bacteria have been observed(65). More importantly, UA,UB, mUA, and 
mUB are the constituents of PE that pass both intestinal and the blood brain 
barriers(68,73).  
Urolithins play a critical role in modulating, inflammation (systemic and 
neuroinflammation), autophagy, cancer, gut integrity(37,38,64,73,74). Previous 
studies have shown urolithins role in modulating LPS induced neuroinflammation 
in vitro(37,38). Studies have also shown that urolithins alleviate both triglyceride 
accumulation in vitro and diet-induced insulin resistance in mice. Taken together, 
urolithins could be a major source of the hepatoprotective and neuroprotective 
effects observed in this present study.  
 
Conclusions 
 PE was able to modulate several key inflammatory molecules in the brain 
including Il-1α, Il-1β, Il-7, Il-11, Tnf, Mapt, Gsk3β, App and Lepr. PE also exhibited 
protective effects on liver pathology and disease associated transcriptional 




a HFD, but showed protective actions against the inflammatory progression of the 
disease. Several potential pathways could be involved in the neuroprotective 
effects derived from PE consumption including the modulating the Gsk3β-Tau-App 
pathway, immune cell recruitment/differentiation, and leptin signaling in the 
hippocampi and PPARγ/PPARα signaling in the liver.  
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Figure Legends 
Figure 1.  PE supplementation is protective against HFD mediated obesogenic 
effects.  Body, white adipose, and liver weight at the time of necropsy. HFD 
feeding significantly increased bodywhite adipose tissue weight, and liver weight. 
PE supplementation with a HFD caused significant reduction in body weight gain 
, WAT weight gain, and liver weight gain. Statistical significance was calculated 
using one-way ANOVA with Fisher’s LSD test where p< 0.05 *, p< 0.01 **, 
p<0.001***, p<0.0001****. 
 
Figure 2.   PE supplementation attenuates HFD-induced hepatic steatosis.   
 2A.) Lipid content is shown as milligram lipid per gram liver. Statistical 
significance was calculated using one way ANOVA with fisher’s LSD test where 
p< 0.05 *, p< 0.01 **, p<0.001***, p<0.0001****. 2B.) Representative H&E 
stained, formalin fixed hepatic tissue sections. 2C.) H&E stained sections were 
scored by a board-certified pathologist from 0 to 4, where 0 is the least and 4 is 
most severe.  Statistical significance was calculated using ranks by one way 
ANOVA with fisher’s LSD. Significance is defined as * significant to the LFD 
control and # significant to the HFD control.  
 
Figure 3.  PE attenuates hepatic genes involved in fatty acid uptake, beta-




expression of fatty acid uptake genes, Fabp1 and Slc27a1. Within a HFD, PE 
prevented high fat induction of Cd36 and Fabp4. 3B.) Mice fed PE within either a 
LFD or HFD presented with reduced expression of fatty acid metabolism genes, 
Cpt1 and Cyp4a14. In addition, PE was protective against high fat induction of 
Ehhadh and Cpt1b. 3C.) PE supplementation within a HFD significantly 
suppressed pro-inflammatory genes, Tnfα, Ccl2, IL6, and Csf2ra. Statistical 
significance was calculated using one way ANOVA where p< 0.05 *, p< 0.01 **, 
p<0.001***, p<0.0001****. 
 
Figure 4.  PE co-administration reduces induction of pro-inflammatory 
interleukins in mouse hippocampi. 4A.) HFD mice displayed elevated levels of 
pro-inflammatory cytokines and chemotractants. PE supplemented HFD mice 
showed reduced IL-1, IL-6, and IL-7 while also increasing anti-inflammatory 
cytokines. 4B.) Pro-inflammatory effects of high fat diet consumption are 
modulated with the inclusion of PE in feed continued. HFD mice displayed 
elevated levels of pro-inflammatory cytokines and chemoattractant. PE 
supplemented HFD mice showed reduced IL-11, IL-18, IFNα, and TNF while also 
increasing anti-inflammatory cytokines 
 Statistical significance was calculated using one way ANOVA where p< 0.05 *, 
p< 0.01 **, p<0.001***, p<0.0001****. 
 
Figure 5.  PE supplementation abrogated AD, macrophage infiltration, and 




neurodegenerative associated genes including cytotoxic T-cell chemotractants, 
and anti-oxidant enzymes. PE supplementation abrogated these AD markers 
within a HFD. 5B.) Macrophage infiltration, metabolic syndrome associated 
ligand and receptor genes are differentially expressed with and without PE 
inclusion. Statistical significance was calculated using one way ANOVA where p< 











































catalyzes the rate-limiting 




0.5068 0.0126 0.2115 
Acot2 
regulation of lipid 
metabolism/intracellular 
levels of free fatty acids 




fatty acid uptake -0.1403 0.0681 0.0931 0.1993 0.3791 0.0005 
Cpt1a 
catalyzes mitochondrial 
uptake of fatty acids for 
beta-oxidation 
0.2213 0.0709 0.3528 0.0106 0.2979 0.0231 
Cpt1b 
rate-controlling enzyme of 
fatty acid beta-oxidation 
 
0.0012 0.7888 0.0085 0.0929 0.01379 0.0151 
Ehhadh 
ezyme in fatty acid beta-
oxidation pathway 
 
0.1890 0.5923 0.5343 0.1534 0.9607 0.022 
Slc271a 
long-chain fatty acids (LCFA) 
uptake into the cell 
 
-0.0033 0.4080 0.0106 0.0223 0.01661 0.0023 
Cidea 
binds to lipid droplets and  
regulates their enlargement 
 
-0.0009 0.3480 0.0009 0.3639 -0.00036 0.6984 
Fabp1 
role in fatty acid uptake, 
transport, and metabolism 
 
0.5884 0.3717 2.6260 0.0029 2.31 0.0059 
Cyp4a14 
oxidation of medium chain 
fatty acids 
 
0.0560 0.9223 1.7810 0.0126 2.51 0.002 
Ppar-g 
nuclear receptor that 
activates the peroxisomal 
beta-oxidation pathway of 
fatty acids 
-0.0075 0.0641 0.0082 0.0478 0.02648 <0.0001 
Csf2ra 
cytokine which controls the 
production and function of 
granulocytes and 
macrophages 
0.0010 0.5277 0.0032 0.0637 0.004056 0.0244 
Ccl2 
chemotactic factor that 

















0.5215 0.003095 0.0018 
Nrf2 
transcription activator that 
up-regulates genes in 
response to oxidative stress 
0.0222 0.1894 0.0314 0.0767 0.03414 0.0583 
Scd1 






0.7153 2.746 0.0022 
Fas 
 
catalyzes fatty acid 
synthesis 
 
-0.0121 0.3359 0.0484 0.0034 0.0688 0.0004 
Fabp4 
role in fatty acid uptake, 





0.9961 0.03848 0.024 
Lpl 
functions as a triglyceride 





0.1488 0.01553 0.0095 
Hmgcs1 






0.3976 0.1616 <0.0001 
Gstm3 
mediates uptake and 






0.0016 -0.01704 0.0729 
Nqo-1 
involved in detoxification 
pathways 
 
-0.0023 0.5287 0.0106 0.0172 0.0164 0.0017 
Gclc 
the first rate-limiting 
enzyme of glutathione 
synthesis 
 
-0.1275 0.1265 0.1020 0.2096 0.3717 0.0011 
Sod1 
eliminates radicals which 
are toxic to biological 
systems 
 
0.6196 0.2826 2.5100 0.0016 2.152 0.004 
Srebf1 
transcriptional activator for 
lipid homeostasis, regulates 





0.6674 -0.09265 0.1489 
Ppar-a 
transcription factor that 
regulates the beta-oxidation 
pathway of fatty acids 
-0.0153 0.8907 0.3676 0.0094 0.4819 0.0021 
Mttp catalyzes the 
transport/export of 





ester, and phospholipid 
Gpam 
catalyzes an essential step 
in glycerolipid biosynthesis 
 
-0.0372 0.2691 0.0341 0.3085 0.1669 0.0007 
IL6 
cytokine involved in 
inflammation/maturation of 
B cells 
0.0001 0.6932 0.0005 0.0025 0.0004 0.0085 
Supplemental Table 1. Hepatic multiplex genes, function, and treatment 
comparisons. Gene functions for the full plex of hepatic genes are described. 
Mean difference and p-value for key treatment comparisons is defined. Statistical 
















induce pro-inflammatory cytokines 
and differentiate Th17 cells 
10.81 <0.0001 -6.425 0.0017 
IL-1β 
 
14.72 <0.0001 -6.26 0.0358 




0.9238 0.0021 0.7429 0.0246 
IL-3 activate basophil and eosinophils, 
recruit phagocytic cells 
 
 
1.708 0.0002 1.013 0.0317 
IL-4 induce Th2 cells, induce tissue 
adhesion and inflammation 
 
 
0.975 <0.0001 0.2917 0.1754 
IL-6 infiltration of leukocytes, T-cell and 
B-cell differentiation, survival of 
cholinergic neurons 
 
2.823 0.0007 -0.7167 0.3802 
IL-7 proliferation of B-cells (pre and 
pro), T-cell survival, induce 
Interleukin synthesis in monocytes 
 
13.22 0.0002 -11.73 0.0012 
IL-9 growth factor for T and Mast Cells, 




1.481 0.0003 -0.4917 0.2225 





1.245 0.0056 -0.5417 0.2592 
IL-11 growth factor for erythroid, 
myeloid and megakaryocyte 
progenitors. Protect epithelial and 
connective tissue. Inhibits 
monocyte and macrophage activity. 
Neuronal development 




IL-13 eosinophil and mast cell 
recruitment, activation and growth. 
MHC II up regulation on B cells 
 
2.025 0.0002 3.9 <0.0001 
IL-15 T-cell proliferation and activation 
(NKT), maintain CD8 memory, 
neutrophil and eosinophil anti-
apoptosis 
 
6.667 0.026 -1.837 0.5872 
IL-16 major chemotractant for CD4/CD8 




69.56 0.0119 6.75 0.8042 
IL-18 induces IFNγ with IL-12, activates 
Th1 or Th2 
 
 
249 <0.0001 -98.82 0.1221 
IL-19 induce Th2 cytokines, IL-6, TNFa 
and IL-10 in monocytes 
 
 
3 <0.0001 0.733 0.17 
IFNα viral response via adaptive immune 
signaling, stimulate DCs antigen 
presentation, macrophage AbDC, 
Promote naïve T-cell growth and 
tumor /virus cell apoptosis 
4.572 0.0022 -2.85 0.0618 
IFNγ Th1 cell cytotoxic response and 
differentiation, upregulates MHC I 
and II expression, inhibits cell 
growth (epithelial), pro-
apoptosis/cell cycle modulation. 
1.113 0.006 0.04286 0.9193 
TNF pro-inflammatory and 
immunosuppressive by initiating or 
limiting severity and duration of 
inflammatory response. 
 
2.141 0.0004 -1.802 0.0041 
MAPT aka Protein Tau, leads to the 




692.7 0.0076 -780.4 0.0074 








APP Amyloid Precursor protein, 
normally involved in neuronal 
plasticity and neuronal 
development. Over expression 
leads to plaque formation and 
microglial activation 
5721 0.0057 4883 0.0369 
PPARγ neuronal depression of 
inflammation associated with 
chronic or acute insult. Glucose 
absorption, lipid balance and cell 
growth/differentiation 
20 0.0073 -2.249 0.7622 
ITGAM leukocyte adhesion, aka 
Macrophage Receptor 1, 
upregulated by TNF, mediate 
complement coated macrophage 
uptake of particles for degradation. 
90.02 0.0026 -29.37 0.3086 
STING stimulates interferon genes in 
response to viral or internal 
pathogens (microbial DNA), 
localizes with autophagy related 
proteins 
16.42 0.0032 -3.786 0.518 
NOS2 induced by IFNγ, TNF and IL-1β. 
Macrophage associated NO 
production, stimulates IL-6 and IL-
8, stimulate epithelial cell growth 
3.604 <0.0001 -0.16 0.7743 
SOD1 anti-oxidant response by binding to 
superoxide radial molecules 
 
 
6170 0.0038 -3242 0.1289 
NFEL2 aka NRF2, interacts with anti-
oxidant response element, 
stimulating Phase II anti-oxidant 
response enzymes (HO-1 and NQO-
1) 
58.44 0.0001 -49.03 0.0024 
CD38 TNFa inducible, Dendritic 
organization in hippocampal 
excitatory neurons, humoral 
immune response 
 
70.13 <0.0001 -8.63 0.5228 
CD70 TNF ligand, activates T and B cells, 
improves cytotoxic function of NK 
cells, proliferation of CD8 T cells 
 




FASL TNF ligand, forms Death Domain 




2.66 0.0002 -1.117 0.1106 
MIF Macrophage Migration Inhibitor 
Factor, response to bacterial 
infection (LPS or DNA), stimulates 
cytokine release in macrophages 
1824 0.008 -936.9 0.1819 
CSF1 Colony Stimulating Factor -1 
induces macrophage infiltration, 
induces pro-inflammatory cytokine 
secretion 
 
39.53 0.0008 -12.74 0.2549 
CD40LG TNF ligand, stimulate T-cell growth 




1.339 0.0217 0.4833 0.4241 
LEPR neuronal stimulation and plasticity, 
food reward (anti-
inflammatory).Pro-inflammatory 
and increased with HFD or 
metabolic syndrome 
13.71 <0.0001 -8.55 0.0039 
CD36 aka FAT, transport fatty acids into 
and out of wide range of cells. 
Inhibited by LPS and HDL, induced 
by cholesterol, CSF, IL-4, insulin and 
glucose.  
47.9 0.0003 -25.13 0.0399 
 
Supplemental Table 2. Hippocampi multiplex genes, function, and 
treatment comparisons. Gene functions for the full plex of hippocampi genes 
measured is described. Mean difference and p-value for key treatment 
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